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ABSTRACT 
The innate immune response is triggered upon the recognition of pathogen-associated molecular 
patterns (PAMPs) by pattern-recognition receptors (PRRs), such as toll-like receptors (TLRs). Upon 
PRR activation, downstream signalling cascades are activated in innate immune cells, resulting in 
the induction of cytokine production, including of interleukin (IL)-10. This anti-inflammatory cytokine 
regulates cellular activation and inflammatory cytokine production, thus promoting immune 
homeostasis and preventing tissue damage upon infection. 
Here, we aimed at investigating the mechanisms underlying the IL-10 expression and production 
upon PRR stimulation of macrophages and dendritic cells (DCs). Upon These cells play distinct 
roles upon infection, as macrophages try to contain infection in situ and DCs will present antigen 
peptides to naïve T cells at the secondary lymphoid organs, thus activating the acquired immune 
response. We also investigated the mechanisms that underlie the differential regulation of cytokines 
of the IL-12 family in macrophages and DCs upon TLR stimulation and its correlation with the 
differential IL-10 regulation in these cells. 
We show that macrophages and DCs vary significantly in the mechanisms that regulate their IL-10 
production. Contrary to macrophages, TLR-stimulated DCs did not produce considerable amounts 
of IL-10. However, Dectin-1 stimulation induced higher IL-10 production by these cells as 
compared to macrophages.  In all, both macrophages and DCs can produce IL-10, but do so in 
response to different stimuli. Our results suggest that differential induction of the MAPK ERK and 
p38 in PRR-stimulated macrophages and DCs likely explains the differences observed for IL-10 
production. Additionally, we found that Dectin-1/TLR2-stimulation led to a reduction in IL-10 
expression by DCs, an unexpected finding that requires further investigation.  In the second part of 
this work, we show that macrophages are limited in their capacity of producing IL-12, IL-23 and IL-
27 upon TLR-stimulation, which is partly due to their high IL-10 production in response to TLR 
triggering. Although IL-10 and IL-12 family members are reciprocally regulated in TLR-stimulated 
macrophages and DCs, this regulation is more pronounced in macrophages. Furthermore, this 
regulation of IL-12 family cytokines by IL-10 occurs at the transcriptional level. 
In summary, this thesis shows that IL-10 expression is tightly regulated, cell type specific and 
dependent on the cell stimulus. This tight regulation of IL-10 has implications on the expression of 
IL-12 family members, and can thus impact cellular activation and the differential priming of Tcells.   
 x 
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RESUMO 
A resposta imunológica inata é ativada após o reconhecimento de padrões moleculares associados 
a agentes patogénicos (PAMPs), por recetores de reconhecimento desses padrões (PRRs). A 
ativação de PRRs, induz a iniciação cascatas de sinalização intracelular que resulta na indução de 
citoquinas, como a interleucina (IL)-10. A IL-10 é uma citoquina anti-inflamatória que regula a 
ativação celular e a produção de citoquinas pró-inflamatórias, como a IL-16, TNF ou a IL-12, 
promovendo assim homeostasia imunológica e prevenindo danos tecidulares após infecção. 
O nosso objetivo era investigar os mecanismos de expressão e regulação da IL-10 produzida por 
macrófagos e células dendríticas (DCs), após ativação por PRRs. Em contexto de infeção estas 
células desempenham funções distintas: enquanto que os macrófagos permanecem in situ  de 
forma a combater a infeção, as DCs migram até aos órgãos linfóides secundários onde 
apresentam péptidos antigénicos, ativando as células T naïve. Foram também explorados os 
mecanismos que estão na base da regulação diferencial da citoquinas da família da IL-12, em 
macrófagos e DCs ativadas via TLR, e qual a sua correlação com a regulação diferencial de IL-10 
nestas células. Neste trabalho mostramos que os mecanismos de regulação da IL-10 em 
macrófagos e DCs são distintos. Ao contrário dos macrófagos, as DCs ativadas via TLR não 
produzem níveis consideráveis de IL-10. Contudo, estimulação via Dectin-1 induziu uma grande 
produção de IL-10 nestas células, comparado com macrófagos. Em suma, ambos os macrófagos 
e as DCs são capazes de produzir IL-10 em resposta a diferentes estímulos. Os nossos resultados 
sugerem que a indução diferencial das MAPK ERK e p38 poderá explicar as diferenças observadas 
na produção de IL-10. Adicionalmente, observamos que a co-estimulação por Dectin-1/TLR2 induz 
uma redução na expressão de IL-10 em DCs, um resultado inesperado que requer uma 
investigação mais aprofundada. Na segunda parte deste trabalho, mostramos que os macrófagos 
estimulados via TLR são limitados na sua capacidade de produzir IL-12, IL-23 e IL-27 devidos à 
sua elevada expressão de IL-10 em resposta a TLRs. Apesar de os membros da família da IL-12 
serem reciprocamente reguladas pela IL-10 em macrófagos e DCs, este mecanismo é mais 
pronunciado em macrófagos. Mostramos também que esta regulação dos membros da família da 
IL-12 pela IL-10 ocorre ao nível trascripcional. 
Em resumo, esta tese mostra que a expressão da IL-10 é regulada de forma especifica para cada 
tipo de célula ou estimulo. Isto tem implicações na expressão nos membros da família da IL-12, 
afetando assim, a ativação celular e de células T.  
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The Innate Immune Response 
 
Innate immunity is the first line of defence against foreign pathogens, providing efficient and 
immediate immune responses1. Activation of innate immune cells, like macrophages, neutrophils 
or dendritic cells is of major importance to control infection and maintain homeostasis. Moreover, it 
constitutes a pre-requisite for the later activation of acquired immune responses2,3.  
Macrophages, originally identified by Metchnikoff, are mononuclear phagocytes with a major role in 
the maintenance of tissue homeostasis, being the major mediators of the innate immune 
response4. Macrophages are highly heterogenic, reflection of their anatomical location and function 
specialization, namely osteoclasts (bone), alveolar macrophages (lung), histiocytes (interstitial 
connective tissue) and kupffer cells (liver)5,6. Moreover, several distinct macrophage populations 
are found either in the gut or in the secondary lymphoid organs6. Also macrophages sub-
populations are found in immune-privileged sites, as the brain (microglia), eyes and testes6. Tissue 
resident macrophages maintain tissue homeostasis by operating as sentinels and control changes 
in physiology, having a role in development, metabolic processes and tissue repair, or in fighting 
pathogen invaders4. Lack of macrophages during tissue development can give rise to illness 
conditions, for example, lack of osteoclasts, caused by loss of bone-reabsorbing macrophages, 
leads to the development of osteoporosis7. Moreover, the role of macrophages in tissue 
development can impact ductal branching, neural networking and angiogenesis7. Tissue stress 
subsequent to injury or infection leads to the activation on tissue macrophages and to the 
recruitment of blood-circulating monocytes into the damaged tissue, which will differentiate into 
mononuclear phagocytes8. Activated macrophages will secrete several inflammatory mediators, 
including cytokines and nitric oxide, which in turn will activate microbicidal mechanisms, namely 
oxidative processes that contribute to the killing of foreign organisms4. For example, during 
Mycobacterium tuberculosis infection, alveolar macrophages will recognize and internalize the 
bacilli into phagosomes9. The phagosome maturation into phagolysosome will provide the release 
of hydrolytic enzymes that constitute one of the major microbicidal activities of macrophages9. 
Furthermore, macrophages activation also induces reactive oxygen species, and, in case of 
interferon-γ (IFNγ) and tumour necrosis factor-α (TNFα) activated macrophages, nitrogen reactive 
species. Macrophages also have a role in tumourigenesis, promoting tumour initiation, progress 
and metastasis10, allergy and autoimmune disorders6. 
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Dendritic cells (DCs), first described by Steinman and Cohn11, sense the microenvironment and 
function as antigen-presenting cells (APCs) with the ability to mount adaptive immune responses. 
DCs have bone-marrow precursors that can give rise to either plasmacytoid DCs (pDC) and 
myeloid/classical DCs (mDC/cDC), commonly referred as DCs12. pDC are present in the blood and 
lymphoid tissues and are specialized in responding to viral infection, through foreign nucleic acid 
recognition, production type I IFN and acquisition of the capacity to present antigens, despite their 
low expression of major histocompatibility complex class II (MHC-II) and co-stimulatory molecules, 
compared to mDC8,12.  
Immature DCs are highly phagocytic cells that upon activation will secrete cytokines to promote 
their maturation and capacity of peptide digestion8. DCs maturation can be triggered upon PRR 
ligand binding13. Mature DCs are present at secondary lymphoid organs and express high levels of 
immunostimulatory molecules, such as peptide-MHC class I and II, as well as T cell co-stimulatory 
molecules as CD80 and CD86, that allow antigen presentation to naïve T cells and T cell 
priming13,14. DCs are cell specialized in tissue sensing, and can be subdivided into several subsets, 
namely: non-lymphoid tissues DCs, epidermal Langerhans cells, tissue-migratory DCs and 
lymphoid organ DCs12. Each DCs subset expresses a different set of PRRs that will induce a 
differential functional maturation, which will shape T cell response13,14. 
DCs and macrophages are specialized innate immune cells, with different functions, which 
combined can orchestrate innate immune responses against foreign pathogens. 
In the next section specific subjects related to innate immune triggering and response development 
are reviewed. 
 
Innate Immune Recognit ion 
 
Innate immune recognition is mediated by germline-encoded PRRs that serve as first-line sentinels 
for pathogen recognition, having the ability to discriminate between different pathogen signature 
molecules, named Pathogen-associated molecular patterns (PAMPs)15.  
PAMPs can derive from virus, bacteria, fungi or parasites and are essential for their survival. These 
molecules include lipids, lipoproteins, proteins and nucleic acids16.  
Furthermore, in case of sterile inflammation, chronic infection or continuous injuries, immune cell 
recruitment is mediated through self-molecules production, named damage-associated molecular 
patterns (DAMPs)17. For instance, in case of cellular death by necrosis, the release of DAMPs, such 
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as extracellular ATP, mitochondrial formaldehyde peptides and mitochondrial DNA results in 
cellular stress or inflammation mediated by PRR activation18,19. 
PRRs can be expressed on the cell surface or in cell endosomes16. Moreover, PRRs can be 
secreted into the bloodstream and tissue fluids, like mannan-binding lectin (MBL), C-reactive 
protein (CRP) and serum amyloid protein (SAP) that are produced by the liver at early stages of 
infection1. Upon PRR activation, several intracellular signalling cascades will be triggered, leading to 
the production of inflammatory cytokines and type I IFN16.  
PRRs are broadly categorized into Toll-like Receptors (TLRs) and non-TLRs, which will be further 
addressed in the next sections.  
 
TLR act ivat ion of innate immune responses 
 
TLRs are type I integral transmembrane glycoproteins, composed by three domains: an 
extracellular (or cytoplasmatic in the case of endosomal TLRs) N-terminus domain that mediates 
PAMPs recognition through leucin-rich repeats (LRRs), a transmembrane domain and an 
intracellular C-terminus domain that triggers signalling pathways through a toll-interleukin (IL) 1 
receptor (TIR)15,16.  
Ten different TLRs were identified in humans, TLR1 to TLR10, nine of them with homology in mice: 
TLR1 to TLR915. In mice 3 additional TLRs were also identified: TLR11 to TLR1315. 
TLRs recognize a wide variety of PAMPs, including triacyl lipoproteins (TLR2/TLR1), diacyl 
lipoproteins (TLR2/TLR6), double-stranded RNA (dsRNA) (TLR3), lipopolysaccharides (LPS) and 
viral envelop lipoproteins (TLR4), flagelin (TLR5), single-stranded RNA (ssRNA) (TLR7 and TLR8), 
genomic rich DNA in unmethylated CpG DNA (TLR9), profin-like molecules (TLR11 and TLR12), 
uropathogenic bacteria (TLR11) and bacterial RNA (TLR13) 16,20,21. The ligand for TLR10 is still 
unknown16.  
Depending on the type of family of recognized microbial molecules, TLRs assume different cellular 
localizations (Figure 1).  In that sense, TLR1, TLR2, TLR4, TLR5, TLR6, TLR11 and TLR12 are 
expressed on the cell surface, whereas TLR3, TLR7, TLR8, TLR9 and TLR13 are expressed in 
endolysosomal compartments16,20,21. Interestingly, after triggering, TLRs that are expressed on the 
cell surface can be endocytosed and signal through endolysosomes15,16,21,22. 
After ligand recognition, TLRs can undergo heterodimerization or homodimerization acquiring a 
horseshoe-like structure that is essential for the initiation of the downstream signalling 
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cascade3,15,16. TIR domain activation leads to the recruitment of bridging adaptors: Myeloid 
Differentiation primary response 88 (MyD88), TIR domain containing adaptor protein (TIRAP), TIR 
domain containing adaptor inducing IFN-ß (TRIF) and TRIF related adapter molecule (TRAM)23. With 
exception of TLR3, all TLRs recruit MyD88 adaptor after ligand recognition15,16. TLR1, TLR2, TLR4 
and TLR6 also use TIRAP as a bridging adaptor between TIR domain and MyD8815,16. TLR3 is the 
only TLR that signals exclusively via TRIF, whereas TLR4 is the only member of this family to signal 
via both MyD88 and TRIF. In the case of TLR4, TRAM is used as a bridging adaptor between TIR 
domain and TRIF (Figure 1). MyD88 dependent pathways recruit IL-1 associated kinase (IRAK) 1 
protein kinases that activates TNF-associated factor (TRAF) 6. In turn, TRAF6 recruits TGF-ß-
activated kinase (TAK) 1 that activates the inhibitor of kappaB kinase (IKK) complex and the 
phosphorylation of mitogen-activated protein kinases (MAPK), leading to the activation of nuclear 
factor –kappaB (NF-κB) subunits and activation of Activated protein 1 (AP-1) transcription factor for 
inflammatory cytokine transcription16(Figure 1).   
 
 
F igure 1:  To l l - l ike receptor  (TLR) s ignal l ing pathway.  From Kumar, H. et al; Toll-like receptors and innate immunity. 
Biochem Biophys Res Commun, 2009. 
 
recognized by CD14 and TLR4 (Table 1). However, several studies
have suggested that C-type lectin receptors such as mannose
receptors, dectin-1, dectin-2 and DC-SIGN play a pivotal role in
immunoprotection [2,17,18,22].
Protozoal PAMPs recognized by TLRs
Many human protozoal infectious diseases such as Sleeping
sickness, Chagas disease, Toxoplasmosis, malaria and various kinds
of leishmaniasis, are caused by Trypanosoma brucei, T. cruzi, Toxo-
plasma gondii, Plasmodium falciparum and Leishmania species,
respectively. Glycoinositolphospholipids (GIPLs) and glycosylphos-
phatidylinosit l anchors (GPI-anchors) from Trypanosoma pecies,
P. falciparum and T. gondii are recognized by TLR2 and TLR4. Mean-
while, unsaturated alkylacylglycerol and lipophosphoglycan (LPG)
from Trypanosoma species and Leishmania species, respectively,
are recognized by TLR2. Genomic DNA of Trypanosoma species
are recognized by TLR9. Interestingly, b-hematin crystal, which is
made from hemin from P. falciparum, is also recognized by TLR9.
Profilin-like protein from T. gondii is reported to be recognized by
mouse TLR11 (Table 1) [17,18].
TLR signaling
Ligand recognitionbyTLRs leads to the recruitmentof variousTIR
domain-containing adaptors such asMyD88, TIRAP, TRIF and TRAM.
The engagement of TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9
and TLR11with their respective ligands recruits MyD88. In addition
toMyD88, TLR1, TLR2, TLR4 and TLR6 recruit TIRAP, which serves as
a linker adaptor between the TIR domain of TLRs and MyD88. Bind-
ingof ligandwithTLR3andTLR4 recruits TRIF. Furthermore, TLR4 re-
cruits TRIF through TRAM, which links between TIR domain of TLR4
and TRIF. This recruitment of adaptors triggers the cascade of signal-
ing pathway and ultimately the activation of transcription factors
such as NFjB and IRFs (Fig. 1). Furthermore, this recruitment also
activatesMAPkinases suchas p38, JNKs andERK1/2,which activates
the AP-1 transcription factor. These transcription factors induce the
transcription of inflammatory cytokines, type I interferons and che-
mokines. Because of the complexity of the pathway, the TLR signal-
ing pathway is categorized into MyD88-dependent and TRIF-
dependent pathways [2,4,17,18].
The MyD88-dependent pathway is utilized by all TLRs except
TLR3. Stimulation with the TLR ligand recruits MyD88 and IRAK
Fig. 1. TLR signaling in conventional dendritic cells, macrophages and plasmatoid dendritic cells. TLR2 (TLR2 in association with TLR1 or TLR6), TLR4, TLR5 and TLR11 are
localized on the cell surface for ligand recognition. TLR3, TLR7, and TLR9 are localized in the endosome, which is transported to the endosome via the ER-localized transporter
protein UNC-93B for ligand recognition in the lumen of endosome. All TLRs, except TLR3, recruit MyD88, while TLR1, TLR2, TLR4 and TLR6 recruit the additional adaptor
TIRAP, which links the TIR domain with MyD88. TLR3 and TLR4 recruit TRIF. TLR4 requires the additional linker adaptor TRAM, which links the TIR domain of TLR4 with TRIF.
Dendritic cells or macrophages stimulated with TLR1, TLR2, TLR5, TLR6, and TLR11 ligands initiate the MyD88-dependent pathway whereas TLR3 ligands initiate the TRIF-
dependent pathway. TLR4 activates both MyD88-dependent and TRIF-dependent pathways. In the MyD88-dependent pathway, MyD88 recruits the IRAK family of proteins
and TRAF6. In turn, TRAF6 activates TAK1. The activated TAK1 activates the IKK complex, which activates NFjB subunits. The activated TAK1 also activates the MAPK
pathway. In the TRIF-dependent pathway, TRIF interacts with RIP1 and TRAF6. Activated TRAF6 and RIP1 activate NFjB and MAPKs. TRIF also interacts with TRAF3 and
activates TBK1/IKKi, which activate IRF3 and IRF7. Plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands activate NFjB and MAPKs via the MyD88-dependent
pathway. To induce type I interferons, MyD88 associates with the IRAK family of proteins. IRAK1 and IKKa activate IRF7. IRAK1 also interacts with TRAF3 and activates IRF7.
The activated NFjB subunits and IRFs are translocated to the nucleus. NFjB and MAPKs initiate the transcription of inflammatory cytokine genes whereas IRFs initiate the
transcription of type I interferons.
H. Kumar et al. / Biochemical and Biophysical Research Communications 388 (2009) 621–625 623
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MyD88- and TRIF-dependent pathways show convergent signalling cascades. TRIF downstream 
signalling also involves TRAF6 for NF-κB activation. Moreover, TRIF can recruit RIP1 that will 
activate TAK116. In addition to NF-κB activation by TRAF6, TRIF can also activate TRAF3 that 
promotes TBK1/IKKi signalling complex that catalyses the phosphorylation of IFN regulatory 
factors (IRF) 3 and induces its nuclear translocation leading to the transcription of type I 
IFN15(Figure 1). 
 Thus, adaptor recruitment initiates signalling cascades that culminate in the activation of 
transcription factors, namely NF-κB and IRFs, or in the phosphorylation of MAPK, such as 
extracellular signal-regulated kinases (ERK) 1/2, p38 and JUN N-terminal kinases (JNK)16. 
Transcription factors activation and nuclear translocation will promote a specific cellular 
transcriptomic program that culminates in expression of many immune mediators, such as 
cytokines16,24 (Figure 1). In addition to the transcription of inflammatory cytokines, such as TNF or 
IL-6, and to type I IFN, the anti-inflammatory cytokine IL-10 is also induced upon TLR triggering, as 
discussed in more detail later. 
The importance of TLRs is illustrated by the fact that several TLR polymorphisms have been 
associated with infection susceptibility and increased risk of cancer development25. For example, 
individuals that carry the D229G polymorphism in TLR4 are more susceptible to septic shock26-28. 
The TLR2 R753Q polymorphism is associated with Borrelia burgdorferi, Treponema pallidum and 
Mycobacterium tuberculosis susceptibility26,29,30. Additionally, the TLR2 R677W polymorphism has 
been associated with increased susceptibility to M. tuberculosis and Mycobacterium leprae26,31,32. 
Since part of the work developed in this thesis regards TLR2, this receptor is described in more 
detail in the next section. 
 
     TLR2  
 
TLR2 is expressed on the cell surface and its triggering relies on the dimerization with either TLR1 
or TLR633. This differential dimerization enables TLR2 to discriminate molecular ligands present in 
the outer membrane of Gram-positive bacteria, as TLR2/TLR1 recognizes tri-acylated lipopeptide 
complexes, whereas TLR2/TLR6 recognizes diacylated lipopeptides34-36.  
Although TLR2 triggering depends on the dimerization with either TLR1 or TLR6, Farhat and 
colleges demonstrate that the downstream cascades activated upon triggering of TLR2/TLR1 or 
TLR2/TLR6 are the same33. Recently, Guan et al described the presence of TLR2/TLR10 pre-
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formed dimers on the cell surface, but the biological function of such combination awaits to be 
determined37. Distinct TLR2 ligands can elicit distinct kinetic profiles of signalling and gene 
expression and consequently each heterodimer may prime a different physiological outcome38. 
Some authors described a possible TLR2 homodimerization, however further studies are needed to 
confirm the biological function of these homodimers34,36. TLR2 triggering can also be facilitated by 
co-receptors, as CD36, which binds to some TLR2 lipopeptides agonists, transferring them to 
CD14 that in turn presents them to the TLR2/TLR6 or TLR2/TLR1 complex39,40. 
More than 175 common TLR2 SNPs of low penetrance alleles have been reported in humans. 
Some of the SNPs promote a shift in the balance of pro and anti-inflammatory cytokines and have 
been associated with increased susceptibility for cancer development25,41-43. Some TLR2 
polymorphisms modulate the host susceptibility or infection aggressiveness by bacteria, like M. 
tuberculosis29,32, Lepromatous leprosy44 and viral infections, namely cytomegalovirus45 or hepatitis 
C virus46. TLR2 polymorphisms can also modulate the risk of development of Alzheimer’s 
disease47, Parkinson’s disease48, among others conditions.  
 
     The TLR2 Signal l ing Cascade 
 
TLR2 triggering activates the MyD88-dependent pathway, which typically induces pro-inflammatory 
cytokines production16,40.  After triggering, TLR2 recruits TIRAP, that functions as a bridging adaptor 
between the TIR domain and MyD88. MyD88 recruits IL-1 receptor associated kinase (IRAK) 4 that 
promotes the phosphorylation of IRAK1. Phosphorylated IRAK1 or IRAK2 promotes TRAF6 
ubiquitination. Ubiquitinated TRAF6 activates the TAB2-TAK1-IKK complex that induces 
ubiquitination and phosphorylation of IκB. IκB degradation promotes NF-κB translocation to the 
nucleus for gene upregulation. TAB2-TAK1 complex can also activate MKK6 resulting in MAPK 
phosphorylation, which in turn will activate AP-1, triggering cytokine gene transcription40. (Figure 2) 
In 1999, Underhill and colleagues described TLR2 recruitment into phagosomes49. In response to 
viral or bacterial ligands, internalized TLR2 activates, by an undetermined pathway, IRF7/3 leading 
to IFN-ß gene up-regulation50 or activates IRF2/IRF1/Signal transducer and activator of 
transcription(STAT)1 for IFN-α gene up-regulation51,52(Figure 2). 
TLR2 activation also leads to the transcription of the anti-inflammatory cytokine IL-10 during 
several viral, fungal and bacterial infectious diseases40. The molecular mechanisms regulating IL-
10 expression upon TLR signalling are detailed later in this thesis. For example, Yersinia pestis 
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hijacks TLR2/TLR6 inducing IL-10 production that leads to DC tolerance, as an evasion 
mechanism53. However, Y. pestis infection also triggers DCs via TLR2/TLR1 leading to the 
production of IL-12 and T cell priming53. The authors showed that TLR2-/- mice had a significant 
decrease in IL-10 production as well as an increase in the production of IFNγ, suggesting that 
TLR2 may have a role as immunomodulator. Furthermore, TLR6-/- mice showed residual levels of 
IL-10 as well as decreased bacterial burden53.  
Nevertheless, absence of TLR2 does not always leads to a decreased bacterial burden. For 
instance, TLR2-/- mice showed increased susceptibility to infection Salmomella54. 
 
 
F igure 2:  TLR2 s ignal l ing pathway. From Oliveira-Nascimento, L. et al; The role of TLR2 in infection and immunity; Frontiers 
in immunology; 2012. 
 
Non-TLR act ivat ion of the innate immune responses 
 
Several families of non-TLR PRRs have been described, including transmembrane proteins, as C-
type lectin receptors (CLRs) and cytoplasmatic proteins, such as Retinoic acid-inducible gene (RIG)-
I-like receptors (RLRs) and Nucleotide-binding oligomerization (NOD)-like receptors (NLRs)55. 
CLRs are transmembrane proteins that include Dectin-1, Dectin-2, manose receptor, C-type lectin 
receptor DC-SIGN and Mincle. CLRs are known to bind to carbohydrate structures present in fungal 
and bacterial cell walls, namely ß-glucan and mannan56.  
Oliveira-Nascimento et al. Role of TLR2 in infection and immunity
FIGURE 1 |TLR2 signaling. After ligand recognition and consequent TLR2
dimer rearrangement, theTIR domain of TIRAP binds theTIR domain of TLR2
and recruits the adaptor protein MyD88. IRAKs are then recruited and IRAK 4
phosphorylates (P) IRAK1, which then initiates auto-phosphorylation.
Phosphorylated IRAK1 dissociates from the complex and activates TRAF6.
Since IRAK1 is rapidly degraded, IRAK2 also activates TRAF 6 in latter
responses. Ubiquitinated (U) TRAF6 triggers the activation sequence
TAB2 –TAK1 – IKK complex. IκB phosphorylation and ubiquitination by the IKK
complex leads to its degradation and release of NF-κB translocation to the
nucleus for gene up-regulation.TAK1 also activates MKK6 for subsequent JNK
and p38 activation, leading to AP-1 activation that triggers gene transcription
of cytokines and accessory molecules. Internalized receptor complex
triggered by a viral ligand can activate by an unknown pathway IRF7/3 to IFN-β
gene up-regulation or IRF2/IRF1/STAT1 for IFN-α gene up-regulation (Underhill
et al., 1999;Watters et al., 2007; Liljeroos et al., 2008; Barbalat et al., 2009;
Dietrich et al., 2010; Dunne et al., 2010). MyD88, myeloid differentiation
primary-response gene 88; TIRAP, TIR adaptor protein; IRAK, interleukin-1
receptor associated kinase; TRAF, TNF receptor associated factor; TAK,
transforming growth factor beta-activated kinase 1; TAB, TAK1-binding protein;
MKK/JNK/P38, MAP kinases, NEMO/IKKs, kinase complex; NF-κB, nuclear
factor-κB; IκB, kinase complex; AP, activator protein; IRF, interferon regulatory
factor, STAT, signal transducer and activator of transcription 1.
killed Listeria monocytogenes (recognized through TLR2), plus a
TLR7/8 ligand, demonstrated synergistic up-regulation of IFN-
γ production and, to a minor extent, IFN-α production (Ghosh
et al., 2007). Although with a different TLR2 ligand (Pam3CSK4),
the opposite outcome of IFN-α was reported with human den-
dritic cells. In this case, TLR2 activation restrained the type I IFN
(IFN-α/β) amplification loop used by TLR4 and TLR7/8 ligands
(Wenink et al., 2009). The controversy can be partially explained
by the fact that TLR2 depletes early IFN-α/β release induced by
TLR9/TLR7, due to transient degradation of IRAK 1, but not later
induction of type I IFN (Liu et al., 2012). The urokinase-type
plasminogen activator receptor was recently described as impor-
tant for optimal MAPK p38 activation and consequent inflam-
mation induced by lipopeptides recognized by TLR2 (Liu et al.,
2011). Mutations of the NOD2 gene results in defective release of
Interleukin-10 (IL-10) from PBMC stimulated with TLR2 ligands,
suggesting another avenue of cross-signaling (Netea et al., 2004a).
Type I interferon (IFN-β/α) production was recently found
to be induced through TLR2 engagement. It was then neces-
sary to postulate an additional signaling pathway to account for
this phenomenon, as type I IFN synthesis requires activation of
IFN regulatory factors (IRF), but not NF-B or AP-1, tradition-
ally seen with TLR2 signaling. The stimulation occurs in the
endosomal environment,which requiresmicrobial or ligand endo-
cytosis. In vitro stimulation of phagocytes with vaccinia virus
(VV) and Lactobacillus acidophilus induced IFN-β production,
while LTA from S. aureus stimulated IFN-α production in murine
macrophages (Liljeroos et al., 2008; Dietrich et al., 2010; Weiss
et al., 2010). It is possible that L. acidophilus also stimulates IFN-α
due to LTApresence. Surprisingly, bacteria but not viruses induced
TLR2-dependent production of IFN-β in dendritic cells, suggest-
ing cell specificity related to the type of microbe. Although not yet
elucidated, thenewlydiscoveredpathwaywasdescribed asMyD88-
dependent and requires IRF1/7 for IFN-β and IRF1/2 for IFN-α
release (Figure 1). Activators of transcription 1 (STAT1), STAT 3,
PI3, and Btk were also reported as part of the signaling cascade
required for IFN-α release induced by LTA. TRIF adapter is not
required for TLR2 activation of interferon production, as it is for
TLR4 and TLR3 (Barbalat et al., 2009).
The intracellular cross-talk scenarios are essential for under-
standing host–microbe interactions, since most invaders have
multiple molecules recognized by multiple innate immune recep-
tors. Investigators have still not been able to relate most of what
has been learned about intracellular regulation of pathogens with
infection outcomes in the host, and this must be the focus for
future studies.
www.frontiersin.org April 2012 | Volume 3 | Article 79 | 5
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Three receptors have been identified in the RLR family, namely: RIG-I, melanoma differentiation-
associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2)57. RLRs recognize 
viral components in several cell types, triggering signalling cascades via Caspase-associated 
molecular pattern (CARD), resulting in the production of type I IFN and pro-inflammatory 
cytokines57. 
With 22 members, the NLR family best-characterized receptors are NOD1 and NOD2 that 
recognize structures of bacterial peptidoglycans, such as g-D-glutamyl-mesodiaminopimelic acid 
(iE-DAP) and muramyl dipeptide (MDP), respectively58. Upon ligand recognition, NOD1 and NOD2 
signal through CARD leading to cytokine secretion58. 
 
     Dect in-1  
 
Dectin-1, a key receptor with critical biological functions upon infection, is a type II transmembrane 
NK-cell-receptor-like C-type lectins expressed in dendritic cells, macrophages, monocytes, 
neutrophils and a subset of T cells59. In contrast to other NK-cell-receptor-like C-type lectin, Dectin-1 
receptor lacks cysteine residues in the stalk region, suggesting that the receptor can function as 
monomer60. Furthermore, Dectin-1 is self-possessed by an immunoreceptor tyrosine-based 
activation motif (ITAM) that mediates immune cellular activation61.  
Dectin-1 mediates the recognition of carbohydrates, specifically ß-1,3-linked and ß-1,6-linked 
glucans, as well as undefined ligands on T cells60,62,63. Engagement of Dectin-1 by ß–glucans 
activates internal signalling cascades that lead to cytokine and chemokine production, including 
TNF, CXC-chemokine ligand 2 (CXCL2, also known as MIP-2), IL-2, IL-6, IL-12 and IL-1061,64-67. 
 ITAM-like motive phosphorylation mediates the triggering of the signalling cascade downstream of 
Dectin-1 through the recruitment of Raf-1 and tandem SH2-domain- containing protein spleen 
tyrosine kinase (SYK) 65. Activation of Raf-1 kinase promotes gene transcription though NF-B 
recruitment56. SYK requirements differ among cell-types60. In macrophages SYK is required for 
respiratory burst induction, but not for phagocytosis68. DCs require SYK for Dectin-1 mediated IL-10 
and IL-12 production, playing also a role in the dectin-1 mediated phagocytosis65,69(Figure 3). 
Recruitment of SYK activates downstream signalling pathways through CARMA-1-related adaptor 
protein CARD9, which binds to mucosal-associated lymphoid tissue lymphoma translocation 
protein (MALT)1 and Bcl-10 to promote IKK kinase complex activation that culminates in the 
activation of the transcription factor NF-κB65,68,70. Dectin-1/SYK signalling depends on CARD9 for 
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NF-κB activation70. CARD9-/- DCs are impaired to produce TNFα upon zymosan stimulation, 
whereas TLR stimulation is not affected. Moreover, IL-6 and IL-2 production is considerably 
decreased in CARD9-/- DCs upon infection with C. albicans 70 Consequently, CARD9-/- mice are 
more susceptible to infection, with higher C. albicans burden70.  
Several authors report the involvement of MAP kinases phosphorylation, such as ERK67,71 in the 
Dectin-1 downstream signalling cascade.  
There are some evidences that suggest that Dectin-1 can induce intracellular signalling through a 
non-SYK signalling pathway, either in macrophages and DCs, however it requires the involvement 
of collaborative signalling from TLRs65,72, which is further detailed in the next section. 
 
Figure 3:  Dect in -1 s ignal l ing Pathway. Adapted from Reid, D. et al; Pattern-recognition receptors: recent insights on Dectin-
1; Current Opinion in Immunology, 2009 
 
Cooperat ion between Dect in-1 and TLR 2 
 
Complex microorganisms present an extensive diversity of PAMPs that may be recognized by 
different PRRs, thus orchestrating the innate immune response.  
The molecular basis underlying the cooperation between Dectin-1 and TLR2 for the induction of 
several cytokines had been subject of investigation. It is known that both receptors collaborate to 
induce optimal cytokine responses in macrophages and dendritic cells. Moreover, SYK and CARD9 
induced signalling by Dectin-1 is required for this collaboration with TLR273,74. Underhill and 
colleges showed that in macrophages and dendritic cells dectin-1 and TLR2 triggering 
igure 1.
Schematic representation of the fungal cell wall and downstream cellular responses following
engagement of Dectin-1 and TLRs on antigen presenting cells (APC). At the top, the interaction
between the yeast cell of a fungus, such as C. albicans, is shown as well as the general
architecture of the fungal cell wall, consisting of overlapping layers of highly mannosylated
proteins, beta glucans (structure within the insert to the right) and chitin. Antigen presenting
cells (APCs), including monocytes, macrophages and DCs, engage fungi and activate host
responses via several PRRs including the Toll-like receptors (TLR) and Dectin-1. Dectin-1 is
alternatively spliced into two functional isoforms, which differ by the presence or absence of
a stalk region (shown in dark blue). Dectin-1 recognises linear or branched 1,3-linked ȕ-glucan,
Reid et al. Page 9
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synergistically led to the production of IL-12 and TNF64. This observation was further corroborated 
for macrophages infected with Mycobacterium smegmatis, Bacillus Calmette-Guérin (BCG), 
Mycobacterium avium and M. tuberculosis75. Moreover, the synergistic effect between Dectin-1 and 
TLR2 can lead to higher induction of IL-23, IL-6 and IL-10 production in dendritic cells, when 
compared to TLR2 activation alone76.  
 
 
Cytokines 
 
In response to PRR activation, innate immune cells produce several cytokines. These cytokines are 
important mediators of innate responses, as well as key molecules for the induction of the acquired 
immune response. Also, IL-10, an anti-inflammatory cytokine, has a prominent function in 
regulating the immune response, preventing inflammatory and autoimmune pathologies24.  
In this thesis special attention was given to IL-10 and IL-12 family cytokines. For this reason, these 
molecules are introduced in more detail below. 
 
Inter leukin-10 
  
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that exerts a suppressive action on immune 
cell activation, controlling the pro-inflammatory cytokine production with repercussions on the 
activation and intensity of the acquired immunity77. IL-10 belongs the IL-10 cytokine family, which 
is located in chromosome one, and also encompasses IL-19, IL-20 and IL-2278,79.  
IL-10 is expressed by innate and acquired immune cells, as dendritic cells, macrophages, mast 
cells, NK cells, eosinophils and neutrophils and T cells subsets as TH1, TH2, TH17, TReg, CD8
+ T 
cells and B cells24. Excess of IL-10 can limit or subvert an immune response, however normal 
levels of IL-10 proved to be extremely important in preventing autoimmune reactions and 
protecting against diseases that result from exaggerated inflammatory responses80. Moreover, IL-10 
abrogation, in the context of an immune response, can result in an increased extent of immune 
pathology, mainly related with tissue damage81,82.  
IL-10 activity is mediated through IL-10 receptor (IL-10R) binding, a transmembranar protein 
formed by 2 subunits, IL-10R1 and IL-10R2, being IL-10R2 an accessory molecule for signalling83. 
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Upon IL-10 binding, signal transduction is initiated through Janus kinase (JAK)/ STAT83,84. The IL-
10/IL-10R binding leads to the phosphorylation of JAK1, expressed by IL-10R1, and Tyk2, 
expressed by IL-10R-2. Tyrosine phosphorylation will thereafter activate STAT3 and STAT1 for 
cytokine and chemokine production83. 
 
     Regulat ion of IL -10 product ion by innate immune cel ls 
 
IL-10 production needs to be finely regulated, as excessive IL-10 expression can limit the immune 
response, whereas absence of IL-10 can lead to immunopathology24. 
Among the several layers for IL-10 regulation, one of them involves chromatin remodelling that 
enhances or silences Il10 gene expression24. The mouse Il10 locus in macrophages, DCs and T 
cells is composed by several DNasel hypersensitive sites (HSSs)85-87. Saraiva et al identified, in 
macrophages and DCs, a decondensed and hyperacetylated HSS-4.5 that suggested to be a 
transcriptionally active element85. Besides chromatin remodelling, epigenetic imprinting of the Il10 
locus is associated with high levels of IL-10 production seen either in TH2 cells and 
macrophages85,88. GATA binding protein 3 (GATA3) was suggested to be the initiator of chromatin 
remodelling and histone acetylation in mice Il10 locus in TH2 cells
85. Since macrophages, DCs and 
other IL-10 producing TH cells do not express higher levels of GATA3, it is possible that chromatin 
remodelling is induced by specific mechanisms depending on the cell type85. 
Macrophages and DCs differ in their expression of PRRs, which translates into a different 
awareness to products derived from pathogens and into differential activation of signalling 
cascades. As a result, the expression of cytokines, including of IL-10, varies between these two cell 
types. As for the signalling cascades induced upon PRR triggering in these cells and regulating IL-
10 expression, a major attention has been dedicated to MAPK. There are three main MAPKs 
involved: ERK, p38 and JNK24. Indeed, Boonstra et al showed that IL-10 production differs in 
macrophages and DCs upon TLR9 ligand CpG activation, a difference that could be related to 
distinct activation of signalling cascades89. Kaiser et al defined a direct relationship between the 
strength of ERK activation and the production of IL-1090. Macrophages, due to a higher activation of 
ERK, showed a greater production of IL-10. The same reasoning applies to DCs, which show lower 
ERK activation upon TLR triggering, and which express intermediate levels of IL-10 and to pDC 
where no ERK activation, nor IL-10, were detected after TLR stimulation90. These findings are 
corroborated with studies in tumour progression locus 2 (TLP2) and NF-κB (precursors of ERK 
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activation) deficient cells 90,91. ERK-independent mechanisms can also prime IL-10 production. 
Activation of p38 upon TLR recognition leads to increased expression of IL-10.  p38 activation 
contributes for IL-10 expression upon CpG stimulation, an agonist of TLR9, and is present in 
signalling pathways of macrophages and DCs90. p38 is activated concomitantly with ERK but their 
signalling cascades do not relate to each other. It is likely that the two signalling pathways induced 
by ERK and p38 cooperate for maximal IL-10 production92,93. As mentioned before, the 
downstream activation of NF-κB and ERK in DCs triggering through Dectin-1 is required for IL-10 
production in these cells. 
 
F igure 4:  IL -10 regulat ion by innate immune cel ls .  From Saraiva, M. and O’Garra, A.; The regulation of IL-10 production 
by immune cells; Nature Reviews Immunology; 2010. 
 
The regulation of IL-10 expression also implies inhibitory processes. IFNγ promotes a negative 
regulation of IL-10 by acting directly through inhibition of ERK and p38, or indirectly by inducing 
compounds such as glycogen synthase kinase 3 (GKS3) which subsequently inhibit the binding of 
AP1 to the IL-10 promoter, resulting in IL-10 transcription inhibition94,95. 
Another layer of regulation of IL-10 gene expression relies on the activation of specific transcription 
factors24. Humans and mice present a high level of homology in the IL-10 promoter, namely in 
certain putative binding sites for transcription factors24. Specific protein 1 (SP1)96, SP397, 
CCAAT/enhancer binding protein-ß (C/EBPß)98, IRF199 and STAT3 have been suggested to bind 
and transactivate IL-10 in macrophages and T cells, either in human and mouse cell lines.  
Moreover, it was showed that NF-κB p50 subunit binds to the IL-10 promoter in a human T cell 
lymphoma cell line100. 
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following TLR activation49. IL-10 expression was only 
partially restored following rescue of ERK activation in 
these cells49, indicating that NF-κB-mediated regulation 
of IL-10 production involves both ERK-dependent and 
ERK-independent mechanisms, as had been suggested 
by previous studies50,51. Furthermore, pathogen trigger-
ing of DC-SIGN in human DCs resulted in the activation 
of RAF1, leading to acetylation of the NF-κB p65 subunit 
and to prolonged and increased IL10 transcription52. This 
effect was only observed after TLR-dependent NF-κB 
activation, suggesting that activation of DC-SIGN can 
modulate TLR-induced IL-10 production52.
The regulation of IL-10 production in response to 
dectin 1 ligation depends on spleen tyrosine kinase 
(SYK)32. SYK is recruited to phosphorylated dectin 1 
(REF. 53) and initiates a signalling cascade that induces 
IL-2 and IL-10 production32. IL-10 production down-
stream of dectin 1 also requires signalling through the 
ERK pathway, despite being independent of TLR activa-
tion54 (FIG. 2a). Furthermore, IL-10 production by FcR 
ligation in the presence of TLR signals in macrophages 
can also lead to ERK activation55. Therefore, ERK activa-
tion is common to several signalling pathways upstream 
of IL10 in macrophages and DCs.
IL-10 expression can also be compromised by inhibi-
tion of p38 signalling in LPS- or CpG-activated macro-
phages45,56–58, primary DCs59 and human peripheral 
blood mo ocytes60. Primary cells lacking the p38 regula-
tor dual-specificity protein phosphatase 1 (DUSP1) have 
prolonged p38 activation and increased levels of IL-10 
expression following TLR stimulation61–63. This could be 
reversed by chemically inhibiting p38 signalling61,62.
Interestingly, abrogation of either ERK or p38 activa-
tion leads to a reduction, but not abrogation, of IL-10 
expression, which suggests that these two pathways might 
cooperate in TLR-induced IL-10 production. Supporting 
this hypothesis, inhibition of both the ERK and p38 
pathways in LPS- or CpG-stimulated macrophages leads 
to an almost complete abrogation of IL-10 production 
(A.O’G., unpublished observations). Furthermore, defi-
ciency of mitogen- and stress-activated protein kinase 1 
(MSK1; also known as RPS6Kα5) and MSK2 (also known 
as RPS6Kα4), which are activated downstream of the p38 
and ERK pathways, correlated with a loss of IL-10 expres-
sion by LPS-stimulated macrophages64.
The production of IL-10 by macrophages and DCs 
is also regulated by the activation of certain inhibitory 
pathways. ERK- and p38-dependent IL-10 production 
is inhibited by IFNγ38 (FIG. 2b). In addition to directly 
blocking TLR-induced MAPK activation, IFNγ induces 
the release of glycogen synthase kinase 3 (GSK3) by 
antagonizing phosphoinositide 3-kinase (PI3K)–AKT 
activation. This leads to inhibition of TLR-induced 
IL-10 production by suppressing the binding of acti-
vator protein 1 (AP1) to the Il10 promoter38. Another 
negative feedback loop controlling IL-10 production by 
macrophages is mediated by IL-10 itself. IL-10 induces 
the expression of DUSP1, which negatively regulates p38 
phosphorylation and thus limits IL-10 production65. By 
contrast, IL-10 positively feeds back to upregulate Tpl2 
expression66, thus providing a positive amplification 
Figure 2 | Signals that induce interleukin-10 expression by cells of the innate immune 
response. a | The expression of interleukin-10 (IL-10) can be induced by Toll-like receptor 
(TLR) or non-TLR signalling in macrophages and myeloid dendritic cells (DCs). Activation of 
TLRs and their adaptor molecules — myeloid differentiation prima y-r spon e protein 88 
(MYD88) and TIR-domain-containing adaptor protein inducing IFNβ (TRIF) — results in  
the activation of the extracellular signal-regulated kinase 1 (ERK1) and ERK2 (which are 
collectively referred to here as ERK), p38 and nuclear factor-κB (NF-κB) pathways. 
Activation of these pathways results in the induction of IL-10 expression, in addition to 
pro-inflammatory cytokines. In myeloid DCs, non-TLR signals through DC-specific 
ICAM3-grabbing non-integrin (DC-SIGN) and RAF1 can augment TLR2-induced IL-10 
production. Furthermore, activation of dectin 1 and the signalling molecules spleen 
tyrosine kinase (SYK) and ERK results in IL-10 production. In macrophages, a role for 
nucleotide-binding oligomerization domain 2 (NOD2) signalling in IL-10 induction, in 
crosstalk with TLR2, has been described. b | Positive and negative feedback loops for IL-10 
regulation in macrophages. The p38 and ERK pathways leading to IL-10 expression by 
macrophages are tightly controlled by interferon-γ (IFNγ) and IL-10 itself. IL-10 feeds back 
to induce the expression of dual-specificity protein phosphatase 1 (DUSP1), which 
negatively regulates p38 phosphorylation and thus limits IL-10 production. IL-10 can also 
positively feed back to upregulate tumour progression locus 2 (TPL2) expression, thus 
providing a positive amplification loop for its own production. In addition, IFNγ can also 
interfere with the phosphoinositide 3-kinase (PI3K)–AKT pathway, releasing glycogen 
synthase kinase 3 (GSK3). As GSK3 normally blocks IL-10 expression by acting on the 
transcription factors cAMP response element-binding protein (CREB) and activator 
protein 1 (AP1), IL-10 production is inhibited by IFNγ through its effects on PI3K. IL-10R, 
IL-10 receptor; MEK, MAPK/ERK1 kinase; MSK, mitogen- and stress-activated protein 
kinase; RIP2, receptor-interacting protein 2; STAT3, signal transducer and activator of 
transcription 3; TRAF3, TNFR-associated factor 3. 
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Finally, post-transcriptional control of IL-10 can be induced by p38 activation, which associated 
with inactivation of Tristetrapolin (TTP), an RNA-destabilizing factor that enables degradation of IL-
10 mRNA by triggering the gathering of RNA decay machinery101-104. We have recently shown that 
differential TLR stimulation can also lead to a differential rate in the Il10 mRNA degradation. 
Compared to TLR2-stimulated macrophages, TLR4 stimulated cells show an increased Il10 mRNA 
stability, which was dependent on TRIF-mediated activation of the p38 signalling pathway (Teixeira-
Coelho, M.; Guedes, J. et al, submitted). 
IL-10 mRNA can also be a target of miR-106, which negatively regulates the IL-10 expression, miR-
466l that up-regulates IL-10 expression by antagonizing the TTP-mediated IL-10 degradation and 
miR-21 that positive regulates IL-10 expression by repressing the mRNA encoding programed cell 
death 4 (PDCD4)105-107. Thus, IL-10 expression is also regulated at the post-transcriptional level by 
miRNA. 
 
The Inter leukin-12 family of  cytokines 
 
The IL-12 family encompasses heterodimeric cytokines, namely IL-12, IL-23, IL-27 and IL-35108. 
The cytokines of the IL-12 family are heterodimeric proteins that comprise a α-chain (p19, p28 or 
p35) and a ß-chain (p40 or ebi3)109. The p40 chain can heterodimerize either with p35, to form IL-
12, or with p19, to form IL-23. Ebi3 can heterodimerize with p28 or p35 to form IL-27 or IL-35, 
respectively108. 
Due to the different biological functions of the bioactive molecules, IL-12 family cytokines are 
provided with positive and negative feedback control. In this sense, IL-12 and IL-23 have pro-
inflammatory characteristics that impact TH1 and TH17 development, respectively
110-112. On the 
other hand, IL-27 is an immunoregulatory cytokine and IL-35 is anti-inflammatory molecule that 
inhibits the development of TReg
113. Therefore, positive regulation is achieved with IL-12 and IL-23 
and negative feedback is regulated by IL-27 and IL-35108,111. 
The biological activity of IL-12, IL-23, IL-27 and IL-35 is induced upon interaction of each cytokine 
with its receptor through JAK/STAT phosphorylation108. The receptor chains are also shared among 
the IL-12 bioactive molecules. IL-12 signals upon binding to the IL-12 receptor (IL-12R), with p40 
interacting with IL-12Rß1, essential for high-affinity binding, and p35 interacting with IL-12Rß2 that 
is required for signal transduction108. IL-23 signals via IL-12Rß1 and IL-23R, being IL-12Rß1 
required for high-affinity binding and IL-23R for the signal transduction108. IL-27 signals via gp130 
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and IL-27R, also known as WSX-1, for functional signal transduction114. IL-35 signal via IL-12Rß2-
gp130 or can signal through homodimerization of gp130 or IL-12Rß2115. Receptor chain sharing 
and competition for binding could help to maintain IL-12 family immune balance. 
The expression of the IL-12 family monomers is tightly controlled at the transcriptional level. p40 
transcriptional regulation has been the subject of extensive studies. It is known that p40 is tightly 
regulated by multiple factors, including NF-κB116, IRF-1117,118, IRF5119, IRF-8117, PU.1, C/EBP120,    
AP-1121 and Rel proteins120. IRF1118,122, IRF3123, IRF5119 represent key factors in the regulation of 
p35 expression. p19 subunit was found to be negative regulated by  RelA124,125 and c-Rel125,126 and 
positively regulated by p52125, all members of the NF-κB family. Additionally, p19 is also regulated 
by IRF5119, ATF-2127, SMAD-3127 and AP-1128. A lot less is known about p28 and ebi3 transcriptional 
regulation. Expression on p28 can be induced via IRF1 and IRF3129. Upon TLR stimulation, NF-κB 
and PU.1 transcription factors promote the transactivation of ebi3 subunit130. 
As referred before, IL-12 is a pro-inflammatory cytokine produced by macrophages, dendritic cells 
and B cells131. IL-12 promotes IFNγ production by activated T cells, constituting a positive feedback 
loop for IL-12 production that facilitates TH1 differentiation
132. As IL-12, IL-23 is a pro-inflammatory 
cytokine predominantly expressed by dendritic cells and phagocytic cells112. IL-23 expression can 
be augmented through T cell CD40 interactions, establishing a positive feedback response that 
enhances IL-23 expression112. IL-23 stabilizes IL-17 expression and TH17 differentiation, however, 
IL-23 is not the differentiation factor for the TH17 phenotype
133. IL-27 is an immunomodulatory 
cytokine produced by antigen-presenting cells. IL-27 induces TReg cell population development (Tr1 
and iTr35) that limits TH1, TH2 and TH17 responses through IL-10 production
134,135. In combination 
with IL-2 or IL-12, IL-27 can exhibit stimulatory effects by inducing IFNγ producing T cells108. 
Moreover, IL-27 can activate STAT1 and that transcription factor T-bet that sensitizes T cells to 
respond to the signal that facilitates TH1 responses
136. 
IL-35 is specifically produced by TReg cells and mediates the suppression of T cell proliferation
113. IL-
35 can generate iTr35 cells and mediates their suppression exclusively via IL-35137. 
It is well established that IL-10 reciprocally regulates the expression of IL-12 and IL-23 
members138,139. The negative regulation that IL-10 exerts on IL-12 production impacts TH1 cell 
differentiation140.  Moreover IL-10 can inhibit TH17 differentiation through negative regulation of the 
IL-23 expression141. In fact, IL-10-/- mice, present high levels of IL-12 and IL-23 expression that 
promote chronic inflammation, which leads to the development of enterocolitis142. 
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Overall, the immune balance is thus established via the differential production of cytokines over 
time and in different anatomical locations and also via the function of IL-10. Understanding how 
these various events are regulated will contribute to uncover targets for immune modulation, with 
an impact in infectious and auto-immune diseases. 
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The equilibrium between pro- and anti-inflammatory cytokines is important to maintain a balanced 
immune response, preventing immunopathology. IL-10 is an anti-inflammatory cytokine, produced 
among several cell types, that regulates immune cellular activation and expression of pro-
inflammatory cytokines. Understanding the molecular mechanisms underlying the regulation of IL-
10 expression in macrophages and dendritic cells is of major importance, considering that IL-10 
exerts a negative control over cell activation and cytokine production. Upon infection, triggering of 
PRRs by PAMPs is a major contributor to the production of IL-10 by innate immune cells. However, 
the molecular mechanisms that are involved in the tight regulation of IL-10 expression by these 
cells need to be better understood. Thus, in the first results chapter of this thesis we aimed at: 
- Understanding how differential TLR versus non-TLR activation, impacts IL-10 production in 
macrophages and dendritic cells; 
- How differential IL-10 expression by PRR-activated macrophages and DCs can be 
modulated by the distinct activation of MAPKs; 
- Investigating the mechanisms underlying multiple PRR activation in the regulation of IL-10 
by dendritic cells. 
 
Reciprocal regulation of IL-12 and IL-23 by IL-10, either in macrophages or in dendritic cells, is 
also of major importance to the development of the immune response, since this family of 
cytokines impacts the differentiation of T helper cells and thus the acquired immune response. 
Thus, in the second part of the results presented in this thesis, we aimed at: 
- Understanding the differential regulation of the expression of all IL-12 family members in 
TLR-stimulated macrophages versus DCs based on their distinct IL-10 production;  
- Investigating how IL-10 impacts the transcription of all monomers of the IL-12 family upon 
TLR stimulation of macrophages and DCs. 
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Mice 
 
C57BL/6 WT and IL-10 deficient mice were purchased from Charles River (Barcelona, Spain), 
TLR2 deficient mice derived from a C57BL/6 background (kindly provided by Anne O’Garra, NIMR) 
were maintained in a closed breeding colony at the ICVS facilities. Bone marrow was extracted 
from age (8 – 12 week old) and sex matched mice. Minimums of 2 animals per strain were used 
for each experiment to overcome cell variability. Animals were euthanized by CO2 poisoning. All 
protocols were performed according to the European Union Directive 86/609/EEC, and were 
previously approved by the national authority Direcção Geral de Veterinária. 
 
Reagents 
 
All reagents were prepared as indicated by each company and used at the following concentration, 
unless otherwise is stated. Pam2CSK4 (Invivogen) and Curdlan from Alcaligenes faecalis (Invivogen) 
were used at 100ng/mL. Pam3CSK4 (Invivogen) was used at 2µg/µL. Zymosan (Invivogen) was 
used at 100µg/mL. CpG (Invivogen) was used at 2µM and Poly I:C (Invivogen) was used at 
20µg/mL. LPS Salmonella Minnesota (Sigma) was used at 25ng/mL. ERK (SB0203580) and p38 
(PD0325901) inhibitors were a kind gift from Anne O’Garra, NIMR and were used at 2,5µM and 
0,1µM, respectively.  
 
Bone marrow der ived macrophages (BMDM) 
 
Bone marrow cells were flushed from mice femurs and tibiae with complete RPMI (cRPMI) medium 
[containing 10% of Fetal Bovine Serum (FBS; Gibco), 1% Sodium pyruvate 100nM (Gibco), 1% 
HEPES 1M (Gibco), 1% L-glutamine (Gibco) and 0,05mM 2-mercaptoethanol (2-ME; Sigma)]. Bone 
marrow cells were cultured in cRPMI supplemented with 20% L929-cell-conditioned medium 
(LCCM) in 8-cm plastic petri dishes (Sterilin) in 8 mL at a density of 0.5 x 106 cells/mL. On the day 
4 of differentiation, 10 mL of supplemented medium was added to the cultures and at day 7 
adherent cells were harvested, counted and stimulated as appropriately. 
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Bone marrow der ived dendri t ic cel ls (BMDC) 
 
Bone marrow cells were flushed from mice femurs and tibiae and cultured in cRPMI medium 
supplemented with 20% granulocyte-macrophage colony-stimulating factor (GM-CSF) in T75 cm2 
flasks in 25 mL at a density of 2 x 105 cells/mL. At day 3 and day 6, 25 mL of supplemented 
medium was added or replaced, respectively. At day 8 cells were harvested, counted and 
stimulated as appropriately. 
 
Cel l  st imulat ion for cytokine product ion 
 
BMDM and BMDC were harvested, re-suspended in 5% FBS cRPMI and the number of cells was 
adjusted to 0.5 x 106 cells/well in a 24-well plate. Cells were stimulated and cytokine release was 
measured after 6 and/or 24 hours post incubation at 37 ºC and 5% CO2 by specific commercial 
ELISA kit for IL-10, IL-6 and TNF (all from eBioscience), according to the manufacturer’s 
instructions. 
 
mRNA stabi l i ty  assay 
 
BMDMs and BMDCs were plated in 24 well plates at 1x106cells/mL in a final volume of 500µL 
and stimulated with TLR agonists as previously described. The mRNA stability was determined with 
the addition to the cell culture medium of Actinomycin D (ActD) (Gibco, Invitrogen), at a final 
concentration of 10 µg/ml. ActD is an antibiotic that binds to DNA, immobilizing the associated 
transcription complex, by interfering with the elongation of RNA. Thus, upon addition of ActD the 
transcription process is stopped and by measuring the amount of RNA present in the culture post- 
ActD addiction we can access the mRNA degradation rates. The cells for total RNA extraction were 
recovered in TRIzol® reagent immediately before ActD treatment and 30, 60 and 90 minutes after 
treatment. The mRNA stability data analysis was performed by calculating the percentage of mRNA 
transcripts present at each time point after ActD addition, considering 100% the level of mRNA 
expression at 0 minutes before the addition of ActD.  
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Quant i tat ive Real - t ime PCR analysis 
 
BMDM and BMDC were cultured in 24-well plates at a density of 0,5 x 106 cells/well. After 
stimulation, RNA was extracted using TRIzol® Reagent (Sigma), according to the manufacturer’s 
instructions. Total RNA was reversed transcribed using Reverter AidTH H Minus Strand cDNA 
Synthesis kit (Fermentas). The resultant cDNA template was used for quantification of target genes 
by real-time PCR analysis with SYBR green detection system. Ubiquitin or HPRT were used as 
housekeeping genes. Each primer was used at a final concentration of 0.4µM.  SYBR Green based 
reactions were performed according to the following parameters: 95ºC for 15 minutes, 39 cycles of 
95ºC for 15 seconds, 58ºC for 20 seconds, and 70ºC for 15 seconds, followed by 65ºC for 5 
seconds and 95ºC for 5 seconds.  TaqMan based reactions were performed according to the 
following parameters: 50ºC for 2 minutes, 95ºC for 10 minutes, 40 cycles of 95ºC for 15 seconds 
and 60ºC for 1 minute, followed by 60ºC for 1 minute. 
The following primers were used:  
 
SYBR Green pr imers 
Ubiqui t in  sense 5’-TGGCTATTAATTATTCGGTCTGCAT-3’ 
Ubiqui t in  ant isense 5’-GCAAGTGGCTAGAGTGCAGAGTAA-3’ 
IL -10 sense 5’-TTTGAATTCCCTGGGTGAGAA-3’ 
IL -10 ant isense 5’-GCTCCACTGCCTTGC-TCTTATT-3’ 
TNF sense 5’-GCCACCACGCTCTTCTGTCT-3’ 
TNF ant isense 5’-TGAGGGTCTGGGCCATAGAAC-3’ 
IL -6 sense 5’-ACACATGTTCTCTGGGAAATCGT6-3’ 
IL -6 ant isense 5’-AAGTGCATCATCGTTGTTCATACA-3’ 
  
TaqMan pr imers 
HPRT Uni gene ID: Mm.299281 
IL12a Uni gene ID: Mm.103783 
IL23a Uni gene ID: Mm.125482 
IL -27 Uni gene ID: Mm.222632 
Ebi3 Uni gene ID: Mm.256798 
 Table 1:  Primers 
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Biological triplicates for each condition were run. Different genes were analysed in the same run to 
avoid inter-run variations. Relative gene expression was determined using the ∆Ct calculation 
method, were the amount of target, normalized to the housekeeping gene Ubiquitin, is given by 
1,8∆Ctx100000, where Ct is the cycle number of detection threshold.  
 
Cel l - lysate preparat ion and Western blot  analysis 
 
BMDM and BMDC were cultured in a 24-well plate at a density of 1 x 106 cell/mL/well in 1%FBS 
cRPMI and rested during 5 hours before stimulation. At each time point, post stimulation, cells 
were washed in ice-cold apyrogenic PBS and resuspended in lysis buffer (containing 100mM Tris-
HCL pH8, 10% glycerol, 1mM EDTA pH8, 5mM MgCl2, 50mM NaCl, 1%NP-40, dH2O) and a 
proteinase inhibitor cocktail (Sigma). Cell lysates were boiled at 95ºC during 5 minutes. Protein 
samples were electrophoresed in a 12% SDS polyacrylamide gel and transferred onto Trans-Blot® 
TurboTM Transfer System (Bio-Rad). Membranes were blocked in 5% low fat milk PBS-Tween 0.1% 
washed in PBS-Tween 0.1% and incubated for overnight at 4ºC with primary antibody, washed and 
incubated for 1 hour at room temperature with HPR-labelled anti-rabbit secondary antibody (Cell 
Signalling). Anti-p-p38 and anti-p38 total were purchased from Cell Signalling Technology; anti-p-
ERK and anti-ERK total were purchased from Invitrogen. Quantity One 1-Danalysis Software version 
4.6.9 for Mackintosh (Bio-Rad) was used for image quantification. 
 
Stat ist ical  analysis 
 
Quantitative data were represented in terms of mean ±	 SEM. Statistical analysis was performed 
using GraphPad Prism version 5.00 for Mackintosh (GraphPad Software, www.graphpad.com). 
Data from independent experiments was analysed by comparison to a defined control value using 
two-tailed Student’s T-tests for two-group analysis and Two-way ANOVA with multiple comparisons 
for grouped analysis. p values <0.05 were considered significant (*p < 0.05; **p < 0.01; *** p < 
0.001). 
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Di f ferent ia l  IL -10 expression by BMDM and BMDC upon TLR2 act ivat ion 
 
Previous data from our laboratory provided initial evidence for a differential regulation of IL-10 
induction in macrophages versus dendritic cells responding to TLR2 stimulation. In particular, the 
profile of IL-10 secretion by bone-marrow derived macrophages (BMDM) and bone-marrow derived 
dendritic cells (BMDC) upon infection with M. tuberculosis was different. To further investigate the 
molecular bases underlying these observations, BMDM and BMDC were stimulated with Pam3CSK4 
(a TLR2/TLR1 pure ligand). Induction levels of Il10 mRNA were assessed by RT-PCR at 30 
minutes, 1, 3, 6 and 24 hours post Pam3CSK4-stimulation (Figure 1A). At 24 hours post 
stimulation supernatants were collected and IL-10 production was measured by ELISA (Figure 1B). 
Our data showed that BMDM and BMDC display a distinct kinetics of Il10 mRNA induction. 30 
minutes post stimulation we observed a 566-fold increase of Il10 mRNA in BMDM compared to 
BMDC, and those high levels of expression were maintained until 1 hour post-stimulation. At 3 
hours we observed a decay in the Il10 mRNA in BMDM and that was maintained throughout the 
time (Figure 1A). BMDC showed a continuous induction of Il10 mRNA until 6 hours post 
Pam3CSK4-stimulation, when the peak of expression was achieved, albeit at levels that were much 
lower than those observed in BMDM (Figure 1A). The distinct Il10 mRNA kinetics between BMDM 
and BMDC had an impact on the IL-10 protein production, with higher quantities being produced 
by BMDM and consistently poor to bellow detection limit in TLR2/TLR1-stimulated BMDC (Figure 
1B). An initial interpretation of the data was that BMDC were not responding to TLR2/TLR1 
triggering.  To further investigate this hypothesis, we measured pro-inflammatory cytokine 
expression and production, namely IL-6 and TNF, upon stimulation of BMDM and BMDC with 
Pam3CSK4. In contrast to Il10, BMDC showed a quicker induction of Il6 mRNA after Pam3CSK4-
stimulation than BMDM, however both cell types achieved the peak of expression at 6 hours post 
stimulation (Figure 1C). Both BMDC and BMDM produced IL-6, although BMDC produced 
significantly higher quantities of this cytokine than macrophages (Figure 1D). Moreover, compared 
to BMDM, BMDC achieved a quicker but lower peak of Tnf mRNA expression at 1 hour post 
Pam3CSK4 stimulation (Figure 1E) that likely contributed to an significantly higher TNF production 
(Figure 1F). 
Based on these observations we concluded that TLR2/TLR1 triggering in BMDC induces a pro-
inflammatory cytokine profile that favors IL-6 and TNF over IL-10 production. In contrast, 
TLR2/TLR1 activation in BMDM favored IL-10 induction. 
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Figure 1: Di f ferent ia l  IL -10 express ion upon TLR2/TLR1 st imulat ion in BMDM and BMDC.  WT BMDM (black) and 
BMDC (grey) were stimulated with Pam3CSK4 – TLR2/TLR1 ligand – and the relative mRNA induction for Il10 (A), IL6 (C) and Tnf 
(E) was assessed by RT-PCR at the indicated time points. All samples were normalized to ubiquitin. Cell culture supernatants were 
collected at 24 hours post stimulation and cytokine production was measured by ELISA for IL-10 (B), IL-6 (D) and TNF (F). Data 
represents mean ± SD of triplicates; *** p ≤ 0.001. Data is representative of two independent experiments. BDL=bellow detection 
limit. 
 
Lack I l10 mRNA induct ion by TLR2 in BMDC is not dependent on the l igand 
dose, nor on the heterodimerizat ion of TLR2 with TLR1 or TLR6 
 
Although in the previous section we demonstrated that lack of IL-10 induction in BMDC stimulated 
via TLR2/TLR1 was not due to a general poor triggering of this TLR, we still considered that the 
strength of the TLR activation may not have been enough for IL-10 expression. We next compared 
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the response of WT BMDM and BMDC stimulated with increasing doses of Pam3CKS4, ranging 
from 0.5 to 10 µg/mL. Cell supernatants were collected at 24 hours and cytokine production was 
measured by ELISA. Our data showed that BMDM produced considerable amounts of IL-10 from 
the lower to the highest concentrations of Pam3CSK4 used, in opposite to what happened to BMDC, 
in which residual amounts of IL-10 were detected only at the higher concentrations of ligand 
(Figure 2A). As before, BMDC responded to all doses of ligand with IL-6 and TNF production, as did 
BMDM (Figure 2B and 2C). Taken together these results suggest that upon TLR2/TLR1 
stimulation, BMDC are not able to produce considerable levels of IL-10.  
It is known that TLR2 can dimerize either with TLR1 or TLR633,36. We investigated if the lack of IL-
10 production by BMDC was dependent on the type of TLR2 dimerization. For that, WT BMDC 
were stimulated with Pam3CSK4 (TLR2/TLR1 ligand) or Pam2CSK4 (TLR2/TLR6 ligand). IL-10 
protein production was measured by ELISA, 24 hours post stimulation (Figure 2D). Our data 
showed that the amounts of IL-10 produced by BMDC upon TLR2 stimulation are consistently low, 
independently of the heterodimerization of TLR2 with TLR1 or TLR6. In all, our data suggest that 
BMDC are poor producers of IL-10 in response to TLR2. 
 
Figure 2:  Cytok ine product ion by BMDC and BMDM upon st imulat ion wi th Pam3CSK4 increas ing doses.  WT 
BMDM (black) and BMDC (grey) were stimulated with the indicated doses of Pam3CSK4 (TLR2/TLR1 ligand) and at 24 hours post-
stimulation cytokine production was determined by ELISA for IL-10 (A), IL-6 (B) and TNF (C). WT BMDC (Grey) were stimulated with 
Pam3CSK4 (TLR2/TLR1 ligand) or Pam2CSK4 (TLR2/TLR6 ligand). Supernatants were  collected at 24 hours post-stimulation and IL-
10 production was measured by ELISA (D). Data represents mean ± SD of triplicates; *** p ≤ 0.001. Data is representative of two 
independent experiments. BDL=bellow detection limit. 
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TLR act ivat ion of BMDM and BMDC leads to dist inct I l10  k inet ics prof i les 
 
Next, we tested whether other TLR-ligands induced IL-10 production in BMDC. We stimulated 
BMDM and BMDC with Pam3CSK4 as a control or with LPS (TLR4 ligand) or CpG (TLR9 ligand). A 
kinetic assay was performed and induction levels for Il10 mRNA were assessed by RT-PCR at 0, 1, 
3 and 6 hours post-stimulation (Figure 3A and 3B). Supernatants were collected at 24 hours post-
stimulation and IL-10 protein was measured by ELISA (Figure 3C and 3D). Our data showed that 
independently of the stimuli, BMDM showed a peak of Il10 mRNA induction at 1 hour post 
stimulation that is followed by a rapid decrease (Figure 3A). As for BMDC, only a modest induction 
of IL-10 expression was observed independently of the TLR stimulation, which was accompanied by 
low IL-10 secretion (Figure 3B and 3D).  
Our data suggest that IL-10 is differently regulated according to the cell type, and that within the 
same cell type, different TLR stimuli leads to differential IL-10 responses. 
 
 
F igure 3:  BMDC are poor IL -10 producers in response to TLR2, TLR4 or  TLR9 s ignal l ing.  WT BMDM (black) and 
BMDC (grey) were stimulated with Pam3CSK4, LPS or CpG for the referred time points. Il10 gene expression was determined by RT-
PCR (A,B). All samples were normalized to ubiquitin. For the same conditions, supernatants were collected at 24 hours post 
stimulation, for analysis of cytokine production be ELISA for BMDC (C) and BMDM (D). Data represents mean ± SD of triplicates;  
*** p ≤ 0.001. Data is representative of one independent experiment.  
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Dect in-1 tr igger ing induces IL-10 expression/secret ion by BMDC 
 
IL-10 induction in innate immune cells may also be triggered by non-TLR stimulation. According to 
the literature, Dectin-1 – ß-glucan receptor – is highly expressed in dendritic cells when compared 
to macrophages. Taking this into consideration, we compared the IL-10 production in BMDM and 
BMDC upon Dectin-1 triggering. For that, we stimulated BMDM or BMDC with different 
concentrations of Curdlan (Dectin-1 ligand) ranging from 2 to 500 µg/mL. IL-10 production was 
measured by ELISA, 24 hours post-stimulation. BMDC were more sensitive to Dectin-1 stimulation 
than BMDM, producing significantly higher amounts of IL-10 than BMDM (Figure 4). The amounts 
of IL-10 produced were dependent on the dose of Curdlan used to stimulate BMDM or BMDC. Our 
data thus indicate that BMDC are not generally impaired to produce IL-10, doing so in response to 
certain stimuli, such as Dectin-1 triggering. 
 
 
Figure 4:  BMDC are more responsive to Dect in -1 s ignal l ing.  WT BMDM (black) and BMDC (Grey) were stimulated with 
increasing doses of Curdlan and supernatants were collected 24 hours post cell stimulation. Cytokine production was tested by 
ELISA. Data represents mean ± SD of triplicates; *** p ≤ 0.001. Data is representative of two independent experiments. BDL=bellow 
detection limit.  
 
Tr igger ing by Dect in-1 induces higher ERK act ivat ion in BMDC than TRL2 
st imulat ion 
 
Upon Dectin-1 and TLR2 triggering, several downstream signalling cascades are activated, 
culminating in MAPK activation40. Moreover, IL-10 production can be modulated by the activation of 
ERK and p3824,90,143. For these reasons, we investigated the activation of ERK and p38 in either 
BMDM or BMDC upon Dectin-1 or TLR2 stimulation. For that, WT BMDC and BMDM were 
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stimulated with Pam3CSK4 (TLR2/TLR6 ligand) or Curdlan (Dectin-1 ligand) during 0, 30, 60, 90, 
120, 180 minutes. Cell lysates were recovered at each time point and protein analysis was 
accessed by western-blot. Our data showed that the activation of p38 occurred in both BMDM and 
BMDC upon TLR2 stimulation, although at an initially higher level for BMDM (Figure 5A). in 
contrast, ERK activation was only transiently detected in BMDM upon TLR2-stiomualtion, but at low 
levels (Figure 5B and 5C). Although the ERK activation triggered by this stimulus appeared faster in 
BMDM, in contrast to what was observed for TLR2 stimulation of BMDC, with Dectin-1 stimulation 
we were able to detect ERK activation for all time points tested (Figure 5E and 5F). 
Considering the data on p38 and ERK activation, we hypothesized that ERK activation was key for 
IL-10 induction in BMDC. To test this hypothesis, WT BMDC were stimulated with Curdlan alone or 
in the presence or ERK or p38 inhibitors. Supernatants were recovered 24 hours post-stimulation 
and IL-10 production was measured by ELISA. Our data showed that IL-10 production by BMDC 
was abrogated in the absence of ERK (Figure 5E). Inhibition of p38 had no effect on the amount of 
protein produced by Dectin-1 stimulated BMDC (Figure 5E). thus, ERK activation is essential for IL-
10 production in BMDC. 
 
Figure 5:  ERK act ivat ion is  required for  IL -10 product ion in BMDC. WT BMDM (black) and BMDC (grey) were 
stimulated with Pam3CSK4 (A-C) or Curdlan (D-E) and cell lysates were recovered at 0, 30, 60, 90, 120 and 180 minutes. ERK and 
p38 activation was accessed by western-blot. WT BMDC were stimulated with Curdlan in the presence or absence of ERK or p38 
inhibitors (G). Cell supernatants were recovered 24 hours post-stimulation and IL-10 protein was measured by ELISA. Data is 
representative of two independent experiments. 
 37 
 
 
Synergy between Dect in-1 and TLR2 promotes an inhibi tory ef fect in the IL-10 
product ion in BMDC 
 
Previous studies suggest that Dectin-1 and TLR2 synergise for maximal IL-10 production in 
macrophages/dendritic cells73. Our data showing that high ERK activation was achieved in BMDC 
stimulated with Curdlan, whereas high p38 activation was observed in TLR2 stimulated BMDC may 
shed light into molecular mechanisms underlying such studies. Indeed ERK activation is known to 
be important for transcriptional induction of IL-1090,144, whereas p38 activation contribute to the 
stabilization of Il10 mRNA103. We therefore questioned if the stimulation of BMDC through Dectin-1 
could rescue IL-10 production in BMDC stimulated via TLR2. For that, we stimulated BMDC with 
Curdlan (Dectin-1 ligand) and Zymosan (Dectin-1+TLR2/TLR6 ligand). Supernatants were collected 
24 hours post stimulation and cytokine production was evaluated by ELISA. In line with the 
literature we observed that BMDC produced higher levels of IL-10 upon TLR2/Dectin-1 stimulation, 
as compared to Dectin-1 stimulation alone (Figure 6A). To further understand the impact of TLR2 
in the collaborative response, we stimulated BMDC with a fixed dose of Pam3CSK4 in combination 
with increasing doses of Curdlan ranging from 0.25 to 100 µg/mL. In parallel WT BMDC were 
stimulated with the same doses of Curdlan alone. Protein production was determined by ELISA, 24 
hours post stimulation. Our data showed that BMDC produced IL-10 protein in a dose dependent 
manner, either when stimulated with Curdlan alone or when stimulated with Curdlan in 
combination with Pam3CSK4 (Figure 6B). Interestingly, when TLR2/TLR1—Dectin-1 signal was 
triggered we saw a significantly reduction in the levels of IL-10 produced by BMDC, suggesting that 
TLR2/TLR1—Dectin-1 signalling has an inhibitory effect in the IL-10 production (Figure 6B). To 
better understand the molecular mechanisms underlying this differential regulation, we decided to 
investigate the transcriptional kinetics of Il10 mRNA upon BMDC stimulation with Dectin-1, TLR2 or 
Dectin-1/TLR2. For that, BMDC were stimulated with Pam3CSK4 (TLR2/TLR1 ligand), Curdlan 
(Dectin-1 ligand) or both ligands combined. Il-10 mRNA induction was measured by RT-PCR at 0, 
1, 3, 6 and 24 hours post stimulation.  Our data showed similar kinetics between BMDC 
stimulated with Curdlan alone and Curdlan combined with Pam3CSK4, (Figure 6C). As before, 
stimulation of BMDC with Pam3CSK4 alone led to poor induction of IL-10 (Figure 6C) and poor IL-
10 production (Figure 6B).  
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Taken together, these results suggest that the differential IL-10 regulation of single Dectin-1 or 
combined Dectin-1/TLR2 stimulation is post-transcriptionally regulated. Since these data contrasts 
what has been shown by other authors73, future experiments are required to explain the observed 
discrepancies. This is discussed in detail in the discussion section of this thesis. 
 
 
 
 
F igure 6:  Inh ib i tory  synerg is t ic  e f fect  induced by TLR2 and Dect in -1 s ignal l ing.  WT BMDC were stimulated with 
Curdlan or Zymozan (A). WT BMDC were stimulated with increasing doses of Pam3CSK4 or Curdlan (B). IL-10 production was 
measured by ELISA at 24 hours post cell stimulation. BMDC were stimulated with Pam3CSK4 alone, Curdlan alone or Curdlan in 
association with Pam3CSK4. Il10  gene expression was measured at the referred time points by RT-PCR. (C) All samples were 
normalized to ubiquitin. Data represents mean ± SEM of triplicates; *** p ≤ 0.001. Data is representative of two independent 
experiment. BDL = bellow detection limit 
 
 39 
 
 
 
 
 
 
 
 
RESULTS – PART I I    
 
 
 40 
  
 41 
BMDM secrete ear l ier and increased IL-10 than BMDC in response to TLR 
st imulat ion 
 
As mentioned in detail before, IL-10 is an anti-inflammatory cytokine known to regulate the 
expression of several pro-inflammatory cytokines upon infection, avoiding immunopathology24. 
Among them, certain cytokines of the IL-12 family have been described to be directly regulated by 
the expression of IL-10.  
Data described in the previous chapter showed that IL-10 is differently expressed in TLR-stimulated 
BMDM and BMDC. We now started by investigating how different TLR stimuli influence the kinetics 
IL-10 production by BMDM and BMDC. WT BMDM and BMDC were stimulated with Pam3CSK4 
(TLR2 ligand), Poly I:C (TLR3 ligand), LPS (TLR4 ligand) or CpG (TLR9 ligand). At 1, 3, 6 and 24 
hours post stimulation supernatants of the stimulated cultures were recovered and IL-10 
production was measured by ELISA. In line with our previous observations and with the literature, 
TLR-stimulated BMDM displayed significantly higher levels of IL-10 than BMDC (Figure1). 
Moreover, for all TLRs tested BMDM showed an earlier production of IL-10 than BMDC (Figure1). 
In summary, our data showed that upon TLR stimulation, BMDM produced earlier and enhanced 
levels of IL-10 than BMDC. 
 
Figure 1:  Ear l ier  and h igher IL -10 product ion in TLR-st imulated BMDM than BMDC. WT BMDM (black) and WT 
BMDC (grey) were stimulated with Pam3CSK4 (TLR2 ligand) (A), Poly I:C (TLR3 ligand) (B), LPS (TLR4 ligand) (C) or CpG (TLR9 
ligand) (D). Supernatants were collected at 0, 1,3, 6 and 24 hours post stimulation and IL-10 production was measured by ELISA. 
Data represents mean ± SD of triplicates; *** p ≤ 0.001. Data is representative of two independent experiments. BDL=bellow 
detection limit. 
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Di f ferent ia l  regulat ion of IL-12p40, IL -12p70, IL -23 and IL -27p28 product ion by 
BMDM and BMDC upon TLR2, TLR3, TLR4 and TLR9 tr igger ing 
 
Taking into consideration the results from Figure 1, we next questioned whether the IL-12 family 
bioactive molecules were being differentially regulated in BMDM versus BMDC and weather that 
would correlate with the differences observed inIL-10 production. To test our hypothesis, WT 
BMDM and BMDC were stimulated with Pam3CSK4 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS 
(TLR4 ligand) or CpG (TLR9 ligand). At 24 hours post stimulation supernatants were recovered and 
IL-12p40, IL12p70, IL-23 and IL-27p28 cytokine production was measured by ELISA. The 
production of IL-35, the fourth member of the IL-12 family, was not measured due to the 
unavailability of immunoassays to this molecule. BMDC produced all IL-12 family cytokines tested 
upon TLR stimulation, with a marked IL-12p40, IL-12p70 and IL-23 production (Figure 2). 
Furthermore, we found that TLR stimulation of BMDM led to poor to no secretion of IL-12p40, IL-
12p70 or IL-23, but did induce the secretion of IL-27, which in case of TLR2 or TL3 stimulation 
was higher than that observed in BMDC (Figure 2). Our data suggest that cytokines of the IL-12 
family are differently regulated in TLR-stimulated BMDM and BMDC. Moreover, the differences 
observed suggest a reciprocal regulation of these cytokines by IL-10. 
 
Figure 2:  Di f ferent ia l  Regulat ion of  IL -12 fami ly  b ioact ive molecules by BMDM and BMDC. WT BMDM (black) 
and WT BMDC (Grey) were stimulated with Pam3CSK4 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS (TLR4 ligand) and CpG (TLR9 
ligand). Supernatants were collected 24 hours post stimulation. IL-12p40 (A), IL-12p70 (B), IL-23 (C) and IL-27p28 (D) production 
was measured by ELISA. Data represents mean ± SD of triplicates. Data is representative of two independent experiments.            
** p  ≤ 0.01, *** p ≤ 0.001. Data is representative of two independent experiments. BDL=bellow detection limit 
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Dist inct t ranscr ipt ional  regulat ion I l12a (p35),  I l12b (p40),  I l23a (p19),  I l27a  
(p28) and I l27b  (ebi3) in BMDM versus BMDC 
 
The IL-12 family cytokines are heterodimers108. Each cytokine is formed by two monomers. IL-12 is 
constituted by p35 and p40, IL-23 by p19 and p40, IL-27 by p28 and ebi3 and IL-35 by p35 and 
ebi3108. Thus an increase in the bioactive molecules as shown in Figure 2 can be due to an 
increase in each or both monomers, which are transcriptionally regulated. Taking into 
consideration the differences observed in the secretion of IL-12 family members upon TLR 
stimulation of BMDM versus BMDC (Figure 2), we next investigated if the differences observed at 
the protein level were related to differential transcription of the various monomers. For that, we 
evaluated the kinetic profile of all IL-12 monomers upon stimulation with TLR ligands. WT BMDM 
and BMDC were stimulated with Pam3CSK4 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS (TLR4 
ligand) or CpG (TLR9 ligand) as before and at 1, 3, 6 and 24 hours post-stimulation the amount of 
Il12a, Il12b, Il23a, Il27a and Il27b mRNA was accessed by RT-PCR and normalized to HPRT. 
BMDC displayed a higher Il12a, Il12b and Il23a mRNA induction, compared to BMDM (Figures 3A-
3L). Nevertheless, BMDM exhibited a higher Il27a and Il27b mRNA induction, compared to BMDC 
(Figure 3M-3T). These results are in line with the protein data (Figure 2), suggesting that the 
regulation of the IL-12 family bioactive molecules in BMDM and BMDC is transcriptional. 
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Figure 3:  Di f ferent ia l  t ranscr ipt ional  regulat ion by TLR st imulated BMDM and BMDC. BMDM (black) and BMDC 
(grey) were stimulated with Pam3CSK4 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS (TLR4 ligand) and CpG (TLR9 ligand). Relative 
mRNA induction for Il12a (A-D), Il12b (E-H), Il23a (I-L), Il27a (M-P) and Il27b (Q-T) was assessed by RT-PCR at the indicated time 
points. All samples were normalized to HPRT. Data represents mean ± SD of triplicates. Data is representative of two independent 
experiments. 
 
IL -10 l imits the product ion of IL -12 family cytokines by TLR-st imulated BMDM 
 
To access the role of IL-10 in the regulation of IL-12 family bioactive molecules, we next 
investigated if the lack of IL-10 impacted the ability of BMDM or BMDC to produce IL-12 family 
cytokines. For that, WT and IL-10-/- BMDM or BMDC were stimulated with the TLR ligands 
Pam3CSK4 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS (TLR4 ligand) and CpG (TLR9 ligand). At 24 
hours post-stimulation supernatants were recovered and IL-27p28 and IL-12p70 cytokine 
production was measured by ELISA.  Both IL-27p28 and IL-12p70 were produced in higher 
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amounts by BMDM in the absence of IL-10, except for TLR3 stimulated BMDM (Figures 4A and 
4C). This result may be explained by the observation that TLR3-stimulated BMDM produced only 
low amounts of IL-10 (Figure 1B). Regarding BMDC, the absence of IL-10 had no effect on the p28 
and p70 production (Figure 4B and 4D), probably due to the low levels of IL-10 that these cells 
produce upon TLR stimulation (Figure 1). 
Our data demonstrated that the presence of IL-10 exerts a negative regulation of IL-12 family 
bioactive molecules impairing or limiting the ability of BMDM to response to TLR stimulation with 
the secretion of these molecules. Of note, whereas the findings obtained for IL-12p70 confirmed 
the studies by other authors89,138, the observation that IL-27p28 secretion by BMDM in novel. Also, 
the effect of IL-10 on IL-23 is currently under investigation, but preliminary results point to a role of 
IL-10 in limiting also IL-23 in TLR-stimulated BMDM. 
 
 
Figure 4:  IL -10 def ic iency led to h igher IL -27p28 and IL -12p17 product ion by BMDM with no impact  in  
BMDC. WT or IL-10-/- BMDM (left) and BMDC (right) were stimulated with Pam3CSK4 (TLR2 ligand), Poly I:C (TLR3 ligand), LPS 
(TLR4 ligand) and CpG (TLR9 ligand). Supernatants were collected 24 hours post stimulation. IL-27p28 (A, B) and IL-12p70 (C, D) 
production was measured by ELISA. Data represents mean ± SD of triplicates;** p  ≤ 0.01, *** p ≤ 0.001. Data is representative of 
two independent experiments. BDL=bellow detection limit 
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IL-10 regulates the product ion of  IL -12 family bioact ive molecules through the 
transcr ipt ional  regulat ion of the monomers 
 
As showed before, IL-12 bioactive molecules are composed by monomers that are transcriptionally 
regulated upon TLR stimulation of BMDM or BMDC (Figure 3). Thus, we questioned how the 
monomers transcriptional profile was regulated by BMDM and BMDC in the presence or absence 
of IL-10. WT and IL-10 -/- BMDM and BMDC were stimulated with LPS (TLR4 ligand) and Il12a 
(p35), Il12b (p40), Il23a (p19), IL27a (p28) and Il27b (ebi3) mRNA induction was accessed by RT-
PCR at 0, 1, 3, 6 and 24 hours post-stimulation. We chose LPS as a stimulus because we 
observed that both BMDM and BMDC were able to produce IL-10 upon TLR4 stimulation      
(Figure 1).  
When compared to WT, IL-10-/- BMDM showed a consistent and marked increase in the 
transcription of IL-12 monomers, which was more pronounced in the cases of Il12a (p35) (Figure 
5A), Il12b (p40) (Figure 5C) and Il27a (p28) (Figure 5G) subunits. IL-10-/- BMDC showed less 
pronounced differences, which were mainly seen in the case of the Il23a (p19) monomer      
(Figure 5B).  
Our data thus suggest that IL-10 regulates the production of IL-12 family bioactive molecules in 
TLR stimulated BMDM through the transcriptional regulation of the IL-12 monomers. 
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Figure 5:  I l -10 def ic iency impacts the t ranscr ipt ion of  IL -12 monomers in TLR-st imulated BMDM. BMDM 
(black) and BMDC (grey) were stimulated with LPS (TLR4 ligand). Relative mRNA induction for Il12a (A; B), Il12b (C, D), Il23a (E, F), 
Il27a (G, H) and Il27b (I, J) was assessed by RT-PCR at the indicated time points. All samples were normalized to HPRT. Data 
represents mean ± SD of triplicates. *** p ≤ 0.001; Data is representative of two independent experiments. 
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IL-10 does not inf luences p19 mRNA stabi l i ty  
 
Interestingly, the expression of Il23a (p19) mRNA in WT versus IL-10-/- TLR-stimulated BMDM and 
BMDC showed a statistical different kinetic, with higher Il23a (p19) induction in IL-10-/- than WT 
cells. These finding is in agreement with the increased secretion of IL-23 in IL-10-/- BMDM or BMDC 
upon stimulation with LPS (data not shown). We next questioned if besides the transcriptional 
regulation, IL-10 was also regulating at the post-transcriptional level the monomer p19. For this, 
WT and IL-10-/-BMDM or BMDC were stimulated with LPS (TLR4 ligand) and at 1 or 3 hours post 
stimulation, Actinomicyn D (ActD) was added to BMDM and BMDC cultures, respectively. The time 
of ActD treatment corresponded to the peak of IL23a mRNA expression observed for BMDM and 
BMDC, respectively. Total mRNA was collected at 30, 60 and 90 minutes post ActD treatment. The 
remaining Il23a (p19) mRNA levels were measured by RT-PCR and normalized to HPRT expression 
and further normalized to the results collected at 0 minutes of ActD treatment for each type of cell. 
Our data showed no differences in the Il23a mRNA stability between WT and IL-10-/-, either for 
BMDM and BMDC (Figures 6A and 6B).  
In summary, our results suggest that the presence of IL-10 regulates IL-23 through monomer 
transcriptional regulation. 
 
 
Figure 6: I l23a  mRNA decay in BMDM and BMDC.  BMBM (A, black) and BMDC (B, grey) were stimulated with LPS (TLR4 
ligand) for 1 and 3 hours, respectively, followed by addition of ActD to stop transcription. After 30, 60 and 90 minutes Il23a mRNA 
was quantified by RT-PCR. All samples were normalized to HPRT. Data represents mean ± SD of triplicates. Data is representative of 
two independent experiments. 
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Macrophages and DCs have distinct physiologic functions in the innate immune response, thus we 
were interested in understanding how these cells are differently triggered upon PAMPs recognition. 
In particular, we wanted to investigate the molecular events triggered in macrophages or DCs 
activation upon TLR and non-TLR stimulus. Moreover, we wanted to understand how these events 
impacted the production of IL-10 and IL-12 family members. 
Data generated in our lab showed that BMDM and BMDC differently express IL-10 upon M. 
tuberculosis and that TLR2 is in this case a major contributor for the production of IL-10 (Teixeira-
Coelho, M.; unpublished data).  Furthermore, several studies show that BMDM are stronger 
producers of IL-10 than BMDC upon TLR2 stimulation89. We thus aimed at firstly understanding 
how IL-10 expression is regulated in TLR2 stimulated BMDM versus BMDC. Our results showed a 
differential IL-10 gene transcription, with BMDM exhibiting higher and earlier Il10 gene expression 
than BMDC. Consistent with these data, BMDM produced higher amounts of IL-10 than BMDC. 
Because BMDC showed residual levels of Il10 gene induction, we questioned if these cells were 
being activated by the TLR2/TLR1 stimulus. To access that, we measured Il-6 and Tnf mRNA 
induction and cytokine production in BMDM and BMDC. We observed that BMDC were producing 
higher amounts of IL-6 and TNF compared to BMDM. Thus, BMDC were not impaired in their 
response to the TLR2/TLR1 ligand, but instead this stimulus was favouring a pro-inflammatory 
response in the near absence of IL-10. Moreover, our results showed that the lack of IL-10 
production by TLR2/TLR1 activated BMDC was not dependent on the ligand concentration, as even 
at higher doses BMDC only produced residual amounts of IL-10. In contrast, IL-6 and TNF 
achieved the maximal levels even at low ligand concentrations.  
Lipopeptides recognition by APCs triggers TLR2 signalling in a TLR1- or TLR6-dependent manner36. 
Seen that the poor IL-10 production in BMDC was not related to a poor response of these cells to 
TLR2/TLR1 ligand, we investigated whether the type TLR2 heterodimerization impacted the 
induction of IL-10. We observed that BMDC were producing modest amounts of IL-10 after being 
stimulated either with TLR2/TLR1 or TLR2/TLR6. This result is in accordance with the work of 
Farhat and colleagues, that suggest that the TLR2 heterodimerization with TLR1 and TLR6 expands 
the ligand spectrum, allowing the recognition of different lipopeptides, but does not lead to 
differential signalling33. 
Because TLR2 heterodimerization and concentration did not impact the amount of IL-10 produced 
by TLR2 stimulated BMDC, we questioned if upon other TLR stimulation IL-10 was produced by 
BMDC. We observed that BMDM expressed consistently higher amounts of IL-10 protein upon TLR 
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stimulation than BMDC, and that Il10 mRNA induction closely paralleled the pattern of protein 
expression. Taking the previous published studies and our systematic approach in measuring IL-10 
mRNA and protein in BMDC versus BMDM stimulated via different TLRs, it is clear that DCs are 
somehow limited to produce IL-10 in response to TLRs.   
It as been previously shown that Dectin-1 triggering leads to IL-10 production71. For instance, in 
response to zymosan, a Dectin-1/TLR2 ligand, BMDC produce high levels of IL-10145, which is 
mediated by the activation of the SYK pathway65. As we show in this thesis, in contrast to what was 
observed with TLRs, in response to Dectin-1 BMDC produced higher amounts of IL-10 than BMDM. 
Furthermore, IL-10 production by Dectin-1 stimulated BMDC was observed even at low doses of 
ligand. Therefore, in spite of the limited production of IL-10 upon TLR stimulation, BMDC are not 
impaired in their capacity of secreting IL-10. We therefore now have a model in which different cell 
types stimulated with different PRR ligands show distinct IL-10 production. Thus, unravelling the 
molecular pathways that discriminate between TLR and Dectin-1 responses in these cells will shed 
light into potential targets for IL-10 modulation. To start addressing this question, we compared the 
kinetics and strength of ERK and p38 activation in BMDM versus BMDC stimulated with TLR2 or 
Dectin-1. Activation of these MAPKs mediates IL-10 production in response to TLR 
signalling90,101,103. We therefore examined the possibility that differential ERK and p38 
phosphorylation could be happening in TLR2 versus Dectin-1-stimulated BMDM and BMDC. We 
observed that ERK activation in BMDC was higher upon Dectin-1 stimulation than upon TLR2 and 
that, consistent with this, inhibition of ERK activation led to abrogation of IL-10 production in 
Dectin-1 stimulated BMDC. Furthermore, we also observed that ERK activation is nearly undetected 
in BMDC upon TLR2 stimulation. This fact may explain the lack of IL-10 production by these cells 
under TLR2-stimulation. I will now be interesting to understand if other TLR stimulation also fail to 
induce ERK activation in BMDC, as well as the molecular determination for this.  The low Il-10 
production under conditions that lack ERK activation is in line with previously published 
studies90,92,144. This is likely due to the requirement of ERK for the induction of cFOS, shown to 
regulate IL-10 expression90,146. Also, ERK is known to be activated downstream of Dectin-1, with a 
major role in the Dectin-1 dependent IL-10 production in BMDM71. IL-10 expression can also be 
regulated by p38 phosphorylation either in TLR4 or TLR9 activated macrophages and dendritic 
cells. However, as we show here, p38 activation is not enough to promote IL-10 induction. Also, in 
the case of BMDC stimulation via Dectin-1 we now show that p38 signalling is not involved in IL-10 
production, thus discriminating the MAPK requirements for maximal IL-10 production upon TLR 
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versus non-TLR signalling. It is possible that the main role of p38 in regulating IL-10 is at the post-
transcriptional level101,103. More recently was showed that, prolonged p38 activation upon TRIF 
activation leads to enhanced IL-10 transcription (Teixeira-Coelho, M.; Guedes,J. et al; submitted), 
thus providing further evidence for the role of p38 as a post-transcriptional regulator of IL-10.  
Dectin-1 and TLR2 can induce collaborative induction of inflammatory responses in macrophages 
and dendritic cells, acting synergistically to mediate cytokine production, namely IL-10, IL-12 or 
TNF64,147. However, the molecular mechanisms underlying the synergistic effect of Dectin-1 and 
TLR2 are not understood. Surprisingly we observed that despite the similar Il10 mRNA induction 
between Dectin-1 and Dectin-1/TLR2 stimulated BMDC, the combination of the two ligands led to a 
reduction in the IL-10 production when compared to single Dectin-1 stimulation. These results may 
suggest that the IL-10 production upon co-stimulation of Dectin-1/TLR2 is being post-
transcriptionally regulated. However, our data opposes that of Dennehy et al suggested, since our 
results suggest an inhibitory effect on the IL-10 production induced by cooperation between Dectin-
1/TLR276. One possible explanation relies on the differences between the ligands that were used: 
we used a commercially available ß-glucan derived from Alcaligenes faecalis whereas Dennehy et 
al used a highly purified ß-glucan isolated from Saccharomyces cerevisiae. The different ß-glycan 
ligand could lead to a differential BMDC activation, and consequently to a distinct IL-10 cytokine 
production. Also, in our study we increased the doses of ß-glucan and maintained that for TLR2 
agonists, whereas Dennehy did the opposite. It is possible that depending on the TLR2/Dectin-1 
balance the signalling cascades differ, thus leading to different IL-10 production. Further 
experiments are needed and will be performed to clarify the observed discrepancies.  
Despite our observations that combined stimulation of BMDC with Dectin-1 and TLR2 may be, at 
least in certain scenarios, inhibitory for IL-10 production, we did observe that Zymosan stimulation 
of these cells led to maximal IL-10 production. This finding was expected, but the underlying 
molecular mechanism is not known. We hypothesized that Dectin-1 may provide the ERK activation 
needed for IL-10 induction. Then TLR2 signalling may bring high p38 activation which could 
stabilize the IL-10 mRNA (Teixeira-Coelho, M. Guedes, J. et al; submitted)101,103. Thus the activation 
of these two MAPK would allow maximal IL-10 production by BMDC. Further studies are needed to 
confirm this hypothesis and also if similar observations are found with Dectin-1 and TLR2. In 
summary, in future experiments we wish to further understand why TLR-stimulated BMDC are poor 
inducers of ERK activation and explore the mechanisms underlying the cooperation between 
Dectin-1 and TLR2.  Moreover, it would be interesting to investigate if Dectin-1 can synergise with 
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other TLRs. Furthermore, because BMDC are maturated from bone-marrow precursors in vitro in 
the presence of GM-CSF, it would be important to confirm our results in mice splenic DCs, which 
are already differentiated, and mostly importantly in monocyte-derived DCs from human samples. 
In addition to the differences at the level of IL-10 production observed in TLR-stimulated BMDM 
and BMDC, these cells also differ with respect to other cytokines. Gerosa el al suggested that 
selective engagement of distinct combinations of PRRs leads to a differential regulation of IL-12 
and IL-23 production by human monocyte derived DC, that consistently express higher levels of IL-
12 and IL-23 than human monocyte derived macrophages147. According to Boonstra and 
colleagues, IL-10 secreted by macrophages and DCs upon TLR4 and TLR9 stimulation, supressed 
their IL-12p70 production89. Recently, Roses et al reported that the differential TLR triggering of 
DCs impacts the regulation of IL-12 and IL-23 production148. Specifically, single TLR agonists tend 
to induce IL-23 production, whereas combined TLR stimulation is required for commitment to IL-12 
production148. In the same work, the authors show that LPS triggering leads to IL-23 production, 
but no IL-12 in monocyte-derived DCs148. Our work shows that, opposite to monocyte-derived DCs, 
BMDC are activated by TLR4 triggering, and are able to produce considerable amounts of IIL-
12p70, as well as IL-12p40, IL-23 and IL-27p28. In line with our results, Siegemund et al showed 
that upon TLR4 triggering BMDC produce consistently higher amounts of IL-12p40, IL-12p70, IL-
23 and IL-27p28 than macrophages149. The data presented here is in line with previous results 
showing that DCs are better producers of IL-12 and IL-23 than macrophages upon TLR triggering. 
However, we now show that this does not apply to all members of the IL-12 family, as production 
of IL-27p28 and expression of p28 and ebi3 were higher in TLR-stimulated BMDM than BMDC. Of 
note, Dennehy et al showed that following TLR2 triggering BMDM and BMDC have similar amounts 
of IL-12p70 production76, whereas we show that TLR2 stimulation led to undetectable levels of IL-
12p70 in BMDM.  
The differential expression of IL-12 and IL-23 in macrophages versus DCs has been previously 
addressed at the molecular level. In particular, IRF5 was shown to be an important player119. 
Taking into consideration the differences in the kinetics of IL-10 production by TLR-stimulated 
BMDM and BMDC we now explored whereas IL-10 could also explain the different production of IL-
12 family cytokines in these cells. To characterize the effect of IL-10 in the regulation of IL-12 
bioactive molecules, we compared WT and IL-10 deficient BMDM and BMDC. Our results showed 
that the absence of IL-10 in BMDM leads to an increased production of IL-12p70 and IL-27p28 for 
all TLRs tested, with exception of TLR3. This result may be explained as TLR3 stimulated BMDM 
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produce low amounts of IL-10. No significant differences were seen between TLR stimulated WT 
and IL-10 deficient BMDC. This result may be related to the fact that TLR stimulated WT BMDC 
produce residual amounts of IL-10, that consequently have no effect on the IL-12p70 and IL-27p28 
production. 
Taken into consideration the results obtained from LPS stimulated WT and IL-10-/- BMDM and 
BMDC, we next showed that IL-10 reciprocally regulates IL-12 family cytokines, through 
transcriptional regulation of IL-12 monomers. Moreover, for p19 and p40 we show no contribution 
of IL-10 for post-transcriptional regulation. 
In summary, in this thesis we demonstrate that BMDM are more potent inducers of IL-10 than 
BMDC, and consequently, BMDC are major producers of pro-inflammatory cytokines, as IL-12. The 
differential triggering of BMDM and BMDC upon the same PRR stimuli is likely related to their 
physiological functions. Macrophages are expected to remain in situ, controlling infection through 
the activation of microbicidal mechanisms and recruitment of inflammatory cells to the lung, 
therefore immunoregulation is essential to prevent tissue damage. As for DCs, PRR triggering will 
induce their maturation and provide the co-stimulation to promote their migration to secondary 
lymphoid organs. The production of stimulatory cytokines is essential for T cell priming and control 
of the magnitude of T cell differentiation, and could be compromised by IL-10.  
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